日本臨牀 別冊 肝・胆道系症候群(第3版)I 肝臓編(上)

出版社: 日本臨牀社
発行日: 2021-01-31
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 肝・胆道系症候群(第3版)I 肝臓編(上)
電子書籍版: 2021-01-31 (第3版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

19,800 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

目次

  • 特集 肝・胆道系症候群(第3版)I 肝臓編(上)
       ―その他の肝・胆道系疾患を含めて―

    Ⅰ.感染症
     1.ウイルス性肝炎
      (1)A型肝炎
      (2)B型肝炎
      (3)Gianotti病、Gianotti-Crosti症候群
      (4)C型肝炎
      (5)D型肝炎
      (6)E型肝炎
      (7)G型肝炎
      (8)アデノウイルス肝炎
      (9)ヘルペスウイルス肝炎(単純ヘルペスウイルス)
      (10)ヘルペスウイルス肝炎(EBウイルス)
      (11)ヘルペスウイルス肝炎(サイトメガロウイルス)
      (12)HIV感染症に伴う肝胆道系合併症
     2.細菌性肝疾患
      (1)化膿性肝膿瘍
     3.肝寄生虫症
      (1)肝住血吸虫症
      (2)肝エキノコックス症
      (3)肝吸虫症
      (4)肝トキソカラ症
      (5)肝蛭症
      (6)アメーバ肝膿瘍
     4.その他の感染症
      (1)肝真菌症(肝アスペルギルス症、肝カンジダ症、肝クリプトコッカス症)
      (2)肝レプトスピラ症、Weil病
      (3)肝結核
      (4)梅毒性肝炎
    II. 生活習慣による肝疾患
     1.脂肪肝全般 総論
     2.NAFL(非アルコール性脂肪肝)
     3.NASH(非アルコール性脂肪肝炎)
     4.アルコール性肝障害 総論
     5.アルコール性脂肪肝
     6.アルコール性肝炎
     7.まだら脂肪肝
     8.糖尿病に伴う脂肪肝
     9.低栄養に伴う脂肪肝
    III. 自己免疫性肝疾患
     1.自己免疫性肝炎
     2.原発性胆汁性胆管炎
     3.原発性胆汁性胆管炎―自己免疫性肝炎のオーバーラップ症候群
     4.原発性硬化性胆管炎
     5.IgG4関連硬化性胆管炎
    IV. 薬物性肝障害
     1.薬物性肝障害:肝細胞障害型
     2.薬物性肝障害:胆汁うっ滞型
     3.薬物性脂肪肝
     4.化学物質による脂肪肝
     5.トロトラスト肝障害(肝腫瘍)
    V. 肝不全
     1.急性肝不全
     2.Acute-on-chronic肝不全
     3.劇症肝炎
     4.慢性肝不全
     5.術後(外傷後)肝不全
    VI. 血行異常
     1.門脈圧亢進症 総論
     2.肝前性門脈圧亢進症
     3.肝外門脈閉塞症
     4.門脈血栓症
     5.肝内型門脈圧亢進症
     6.肝内型前類洞性門脈圧亢進症
     7.特発性門脈圧亢進症
     8.Sinusoidal obstruction syndrome (SOS)
     9.肝内肝静脈閉塞(後類洞性)門脈圧亢進症候群
     10.Budd-Chiari 症候群
     11.門脈大循環短絡症
     12.肝外門脈瘤
     13.肝内門脈瘤
     14.門脈系の先天異常
     15.肝性脳症
     16.肝内動門脈短絡(A-P shunt)
     17.肝内動静脈短絡(A-V shunt)
     18.肝梗塞と虚血性肝障害
     19.肝動脈瘤
    VII. 肝内胆汁うっ滞症
     1.肝内胆汁うっ滞
     2.Alagille症候群
     3.進行性家族性肝内胆汁うっ滞症、良性反復性肝内胆汁うっ滞症
     4.遺伝性胆汁うっ滞
      (1)Aagenaes 症候群
      (2)North American Indian childhood cirrhosis (NAIC)
      (3)Nielsen症候群(グリーンランドエスキモーの子供における
          致死的家族性肝内胆汁うっ滞症候群,FIC1欠損症,
          進行性家族性肝内胆汁うっ滞症1型)
      (4)先天性胆汁酸代謝異常症
     5.シトリン欠損による新生児肝内胆汁うっ滞症(NICCD)
     6.体質性黄疸
      (1)Gilbert症候群
      (2)Crigler-Najjar症候群
      (3)Rotor症候群
      (4)Dubin-Johnson症候群
      (5)Lucey-Driscoll 症候群(一過性家族性新生児高ビリルビン血症)
     7.新生児の経静脈栄養に伴う胆汁うっ滞症
     8.肝移植後胆管合併症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 感染症

P.7 掲載の参考文献
1) Lemon SM, et al : Type A viral hepatitis : A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol 68 : 167-184, 2018. (doi : 10.1016/j.jhep.2017.08.034)
3) Kaplan G, et al : Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 15 : 4282-4296, 1996.
5) Kojima T, et al : Hepatitis A virus outbreak ; a possible indicator of high-risk sexual behavior among HIV-1 infected homosexual men. Jpn J Infect Dis 52 : 173-174, 1999.
6) Yamamoto C, et al : Very low prevalence of anti-HAV in Japan : high potential for future outbreak. Sci Rep 9 : 1493, 2019. (doi : 10.1038/s41598-018-37349-1)
7) 感染症情報センターホームページ : 2012年第1週から2018年第42週までの感染症発生動向調査におけるA型肝炎の報告. [https://www.niid.go.jp/niid/ja/hepatitis-a-m/hepatitis-a-idwrs/8423-hepa-181120.html]
8) Hutin YJ, et al : A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 340 : 595-602, 1999.
9) Hirata R, et al : Patients with hepatitis A with negative IgM-HA antibody at early stages. Am J Gastroenterol 90 : 1168-1169, 1995.
11) Ida S, et al : Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 34 : 379-385, 2002.
13) Vento S : Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat 7 (Suppl 1) : 7-8, 2000.
P.13 掲載の参考文献
1) B型肝炎治療ガイドライン (第3版) (日本肝臓学会肝炎診療ガイドライン作成委員会編), 2017.
P.16 掲載の参考文献
1) Gianotti F : Relievi di una particolare casistica tossinfettiva caratterizzata daeruzione eritemato-infiltrativa desqumativa a focolai lenticolari, a sede elettiva acroesposta. Giornale Italiano di Dermatologia 96 : 678-697, 1955. [Report on a special case of toxic infection characterized by a desquamative erythemato-infiltrative eruption with lenticular foci and a selective localization at the extremities]. Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr 96 : 678-697, 1955.
2) Crosti A, Gianotti F : Dermatose eruptive acro-situee d'origine probablement virosique. Dermatologia 115 : 671-677, 1957. [Eruptive dermatosis of probable viral origin situated on the acra]. Dermatologica 115 : 671-677, 1957.
4) 戸田剛太郎 : Gianotti病. Gianotti-Crosti症候群 ; 感染症. 別冊日本臨牀領域別症候群 肝臓編 (上巻), p24-26, 日本臨牀社, 1995.
5) 藤澤知雄 : Gianotti-Crosti症候群. 小児内科 42 : 185-189, 2010.
6) 宮城拓也, 高橋健造 : Gianotti症候群. 小児内科 48 : 524-527, 2016.
7) 戸倉新樹 : B型肝炎ウイルスワクチン接種後に発症したGianotti-Crosti症候群. 皮膚病診療 40 : 63-66, 2018.
8) 下田敏彦, ほか : Gianotti病皮膚病変の発生機序に関する免疫組織学的研究. 肝臓 21 : 517-529, 1980.
9) Toda G, et al : Infantile papular acrodermatitis (Gianotti's disease) and intrafamilial occurence of acute hepatitis B with jaundice : age dependency of clinical manifestations of hepatitis B virus infection. J Infect Dis 138 : 211-216, 1978.
10) Ishimaru Y, et al : An epidemic of infantile papular acrodermatitis (Gianotti's disease) in Japan associated with hepatitis-B surface antigen subtype ayw. Lancet 1 (7962) : 707-709, 1976.
12) Michitaka K, et al : Tracing the history of hepatitis B virus genotype D in western Japan. L Med Virol 78 : 44-52, 2006.
13) 恩地森一, ほか : 愛媛Gianotti病顛末記. 肝臓 47 : 518-523, 2006.
14) 岩崎栄典, ほか : Gianotti-Crosti症候群を合併した成人発症B型急性肝炎の1例. 日消誌 110 : 1657-1662, 2013.
15) Matsuura K, et al : Characteristics of geographic distributions and route of infection for hepatitis B virus genotype D in Ehime area in western Japan. Hepatol Res 37 : 255-262, 2007.
P.22 掲載の参考文献
1) Global hepatitis report, 2017 (World Health Organization).
2) 厚生労働省. [http://www.mhlw.go.jp]
4) Tanaka J, et al : Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology 54 : 185-195, 2011.
7) C型肝炎治療ガイドライン 第8版 (日本肝臓学会編), 2020.
9) Li DK, et al : The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals : An ERCHIVES study. Hepatology 67 : 2244-2253, 2018.
P.26 掲載の参考文献
2) Stockdale AJ, et al : The global prevalence of hepatitis D virus infection : Systematic review and meta-analysis. J Hepatol 73 : 523-532, 2020.
4) Abbas Z, et al : Hepatitis D : Scenario in the Asia-Pacific region. World J Gastroenterol 16 : 554-562, 2010.
5) Liaw YF, et al : Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection : a prospective study. J Infect Dis 162 : 1170-1172, 1990.
6) 矢野右人, 井上長三 : δ型肝炎の臨床と日本における現況. 日本臨牀 47 : 715-720, 1989.
7) 高橋雅春, ほか : D型肝炎の診断法の確立と分子疫学的研究の成果. 臨床とウイルス 37 : 329-336, 2009.
9) Rosina F, et al : Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 117 : 161-166, 1999,
12) Niro GA, et al : Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta, Hepatology 44 : 713-720, 2006.
13) Zhang FL, Casey PJ : Protein prenylation : molecular mechanisms and functional consequences. Annu Rev Biochem 65 : 241-269, 1996.
14) Bogomolov P, et al : Treatment of chronic hepatitis D with the entry inhibitor myrcludex B : First results of a phase Ib/IIa study. J Hepatol 65 : 490-498, 2016.
P.30 掲載の参考文献
1) 岡本宏明 : E型肝炎ウイルスのウイルス学的特徴. 日本臨牀 73 (増刊 : 新ウイルス性肝炎学) : 620-628, 2015.
2) 岡本宏明 : E型肝炎診療の最前線. 日本内科学会雑誌 107 : 1826-1832, 2017.
3) 世界保健機関ウェブサイト. [https://www.who.int/news-room/fact-sheets/detail/hepatitis-e]
4) Takahashi M, et al : A nationwide survey of hepatitis E virus infection in the general population of Japan. J Med Virol 82 : 271-281, 2010.
5) 国立感染症研究所ウェブサイト. [https://www.niid.go.jp/niid/ja/encycropedia/392-encyclopedia/319-hepatitis-e-intro.html]
6) 日本赤十字社ウェブサイト. [http://www.jrc.or.jp/mr/product/information/pdf/info_202007.pdf]
7) European Association for the Study of the Liver : EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 68 : 1256-1271, 2018.
8) Kamar N, et al : Ribavirin for Hepatitis E Virus Infection After Organ Transplantation : A Large European Retrospective Multicenter Study. Clin Infect Dis 71 : 1204-1211, 2020. (DOI : 10.1093/cid/ciz953)
9) Owada Y, et al : A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan. Transplantation 104 : 437-444, 2020.
10) Xiamen Innovax Biotechウェブサイト. [http://www.innovax.cn/en/news_view.aspx?newsCateid=56&cateid=56&NewsId=1005]
P.33 掲載の参考文献
5) Stapleton JT, et al : The GB viruses : a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol 92 : 233-246, 2011.
6) Masuko K, et al : Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 334 : 1485-1490, 1996.
7) 小島眞樹, ほか : B型, C型及び非B非C型の各種慢性肝疾患患者におけるHGVの感染頻度と感染経路. 肝臓 38 : 535-540, 1997.
8) 新沢陽英, ほか : HCV感染多発地区におけるHGV感染の疫学的研究. 日本臨牀 55 : 609-612, 1997.
11) Horemheb-Rubio G, et al : High HPgV replication is associated with improved surrogate markers of HIV progression. PLoS ONE 12 : e0184494, 2017.
13) Greenhalgh S, et al : Fighting the Public Health Burden of AIDS With the Human Pegivirus. Am J Epidemiol 188 : 1586-1594, 2019.
P.35 掲載の参考文献
1) Murase Y, et al : Fulminant adenovirus hepatitis with adenovirus-associated esophagitis complicating malignant lymphoma. Pathol Int 68 : 259-261, 2018.
2) Kawashima N, et al : Fulminant adenovirus hepatitis after hematopoietic stem cell transplant : Retrospective real-time PCR analysis for adenovirus DNA in two cases. J Infect Chemother 21 : 857-863, 2015.
3) Trovato FM, et al : ADV36 adipogenic adenovirus in human liver disease. World J Gastroenterol 20 : 14706-14716, 2014.
4) Boge CLK, et al : Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. Pediatr Transplant 23 : e13510, 2019.
5) 国立感染症研究所 : アデノウイルス解説ページ. [https://www.niid.go.jp/niid/ja/adeno-pfc-m/2110-idsc/4th/4325-adeno-virus-page.html]
6) Ginberg HS : Adenoviruses. In : Microbiology, 3rd ed, Harper & Row Publishers, New York, 1990.
7) 青山友三, ほか : アデノウイルス. ウイルス感染症の臨床と病理, p77, 医学書院, 1991.
P.40 掲載の参考文献
1) Schiodt FV, et al : Viral hepatitis-related acute liver failure. Am J Gastroenterol 98 : 448-453, 2003.
2) McCormack AL, et al : HSV Hepatitis in Pregnancy : A Review of the Literature. Obstet Gynecol Surv 74 : 93-98, 2019.
3) Calix RX, et al : Acute Herpes Simplex Virus Hepatitis in Pregnancy. Obstet Gynecol 135 : 396-400, 2020.
4) Gutierrez C, et al : A unique presentation of acute liver failure from herpes simplex virus hepatitis. Transpl Infect Dis 18 : 592-594, 2016.
5) Fernandez-Nieto D, et al : A case of atypical disseminated herpes simplex virus 1 with hepatitis in a liver transplant recipient : the need for dermatologic evaluation. Dermatol Online J 26 : 13013, 2020.
6) Goel K, et al : Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn's Disease : A Case Report. Clin Med Insights Case Rep 12 : 1179547619858979, 2019.
7) Shlien RD, et al : Fulminant herpes simplex hepatitis in a patient with ulcerative colitis. Gut 29 : 257-261, 1988.
8) Poley RA, et al : Herpes Simplex Virus Hepatitis in an Immunocompetent Adult : A Fatal Outcome due to Liver Failure. Case Rep Crit Care 2011 : 138341, 2011.
9) Ngo DQ, et al : Herpes Simplex Virus Type 1 Hepatitis in an Immunocompetent Female After Laparoscopic Cholecystectomy, Cureus 12 : e9529, 2020.
10) 今一義ほか : [連載 : 検査値の読み方] 急性肝不全をきたした単純ヘルペスウイルス肝炎の1例. 臨牀消化器内科 32 : 1293-1296, 2017.
12) Natu A, et al : Herpes Simplex Virus Hepatitis : A Presentation of Multi-Institutional Cases to Promote Early Diagnosis and Management of the Disease. Case Reports Hepatol 2017 : 3180984, 2017.
13) Soliman M, et al : A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology. Case Reports Hepatol 2019 : 4808143, 2019.
14) Ahmed A, et al : Herpes Simplex Virus-2 Hepatitis : A Case Report and Review of the Literature. Case Rep Med 2020 : 8613840, 2020.
P.44 掲載の参考文献
2) White NJ, Juel-Jensen BE : Infectious mononucleosis hepatitis. Semin Liver Dis 4 : 301-306, 1984.
3) Katz BZ, Miller G : Epstein-Barr virus infections. In : Krugman's Infectious Diseases of Children, 10th ed, p98-115, Mosby, 1998.
4) Jenson HB : Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr 12 : 263-268, 2000.
5) Hess RD : Routine Epstein-Barr virus diagnostics from the laboratory perspective : still challenging after 35 years. J Clin Microbiol 42 : 3381-3387, 2004.
6) Dunmire SK, et al : Infectious mononucleosis. Curr Top Microbiol Immunol 390 (pt 1) : 211-240, 2015.
7) 武村俊之, ほか : 伝染性単核球症. 皮膚病診療 21 : 335-338, 1999.
8) Crum NF : Epstein Barr virus hepatitis : case series and review. South Med J 99 : 544-547, 2006.
9) Mellinger JL, et al : Epstein-Barr virus (EBV) related acute liver failure : a case series from the US Acute Liver Failure Study Group. Dig Dis Sci 59 : 1630-1637, 2014.
10) Papatheodoridis GV, et al : Fulminant hepatitis due to Epstein-Barr virus infection. J Hepatol 23 : 348-350, 1995.
11) Evans AS : Infectious mononucleosis. In : Textbook of Hematology (ed by Williams I, et al). p843-853, McGraw-Hill, New York, 1972.
12) 町井彰 : 伝染性単核症の臨床とその肝障害. 日本医事新報 3408 : 3-12, 1989.
13) Niller HH, et al : Regulation and dysregulation of Epstein-Barr virus latency : implications for the development of autoimmune diseases. Autoimmunity 41 : 298-328, 2008.
14) 石崎文雄, ほか : 伝染性単核症95例の耳鼻咽喉科的所見. 日耳鼻 90 : 844-852, 1987.
15) Schechter S, et al : Epstein-Barr Virus Hepatitis : A Review of Clinicopathologic Features and Differential Diagnosis. Arch Pathol Lab Med 142 : 1191-1195, 2018.
P.49 掲載の参考文献
1) 日本造血細胞移植学会 ; 宮本敏浩, ほか : 造血細胞移植ガイドライン ウイルス感染症の予防と治療サイトメガロウイルス感染症 (第4版), p1-6, 日本造血細胞移植学会, 2018.
2) Cannon MJ, et al : Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20 : 202-213, 2010.
4) 山本和秀, ほか : わが国における急性肝炎の現状 全国調査 2008-2011, p1-10, 中外医学社, 2012.
5) 四柳宏 : EBVやHCMVによる肝炎 (伝染性単核球症). 診断と治療 101 : 1339-1342, 2013.
6) Leonardsson H, et al : Hepatitis due to Epstein-Barr virus and cytomegalovirus : clinical features and outcomes. Scand J Gastroenterol 52 : 893-897, 2017.
7) Al-Omari A, et al : Cytomegalovirus infection in immunocompetent critically ill adults : literature review. Ann Intensive Care 6 (1) : 110, 2016.
8) 竹中克斗 : 同種造血幹細胞移植後のサイトメガロウイルス感染対策. 日本輸血細胞治療学会誌 65 : 519-524, 2019.
9) 川名尚 : 産婦人科領域の感染症の現状と最近のトピックス. 産科と婦人科 85 : 877-886, 2018.
10) Society for Maternal-Fetal Medicine (SMFM) ; Hughes BL, et al : Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 214 : B5-B11, 2016.
P.53 掲載の参考文献
1) エイズ動向委員会報告 : エイズ予防情報ネット (AIDS Prevention Information Network : API-Net). [https://api-net.jfap.or.jp/]
2) 抗HIV治療ガイドライン 2020年3月 (研究分担者 : 四本美保子, 研究代表者 : 白阪琢磨). 令和元年度厚生労働行政推進調査事業費補助金エイズ対策政策研究事業HIV感染症及びその合併症の課題を克服する研究班, 2020.
3) Benhamou Y, et al : for the Multivirc Group : Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30 : 1054-1058, 1999.
4) Smith CJ, et al : Trends in underlying causes of death in people with HIV from 1999 to 2011 (D : A : D) : a multicohort collaboration. Lancet 384 : 241-248, 2014.
5) Ishida H, et al : Favorable outcome with direct-acting antiviral treatment in hepatitig. C patients coinfected with HIV. Hepatol Res 49 : 1076-1082, 2019.
6) 四柳宏, ほか : HIV感染者のC型慢性肝炎に対するソホスブビルを用いた経口抗HCV療法. 日本エイズ学会誌 21 : 27-33, 2019.
7) Tanaka S, et al : Outbreak of hepatitis A linked to European outbreaks among men who have sex with men in Osaka, Japan, from March to July 2018. Hepatol Res 49 : 705-710, 2019.
8) Bennett JE, et al : Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed, p1659-1660, Elsevier, 2019.
P.58 掲載の参考文献
1) 森山光彦 : 肝感染症. カラー版 消化器病学 基礎と臨床 (浅香正博, ほか編), p1264-1269, 西村書店, 2013.
2) Davis J, McDonald M : Pyogenic Liver Abscess. Up To Date. [http://www.uptodate.com/contents/pyogenic-liver-abscess]
3) 町田洋太 : ガス産生肝膿瘍, 肝ガス壊疽 : 感染症, 細菌性肝疾患. 別冊日本臨床新領域別症候群シリーズ No. 13 肝・胆道系症候群 (第2版) I 肝臓編 (上), p76-78, 日本臨牀社, 2010.
4) 重福隆太, ほか : 過去20年間における肝膿瘍153例の臨床的検討. 肝臓 59 : 466-480, 2018.
5) Thng CB, et al : Gas-forming pyogenic liver abscess : A world review. Ann Hepatobiliary Pancreat Surg 22 : 11-18, 2018.
6) 江藤亮大郎, ほか : 切除不能膵癌に対する化学療法中にClostridium perfringens感染による肝ガス壊疽を生じ急激な経過で死亡した1例. 日本外科感染症学会雑誌 16 : 75-79, 2019.
7) Echigoya R, et al : Hepatic Gas Gangrene. Intern Med 54 : 1319, 2015.
8) 中野雅人, ほか : 肝ガス壊疽による播種性血管内凝固症候群, 多臓器不全から救命しえた1例. 日本消化器外科学会雑誌 46 : 416-423, 2013.
9) 重福隆太, ほか : Streptococcus anginosus groupによる化膿性肝膿瘍の3症例. 日本消化器病学会雑誌 110 : 1468-1480, 2013.
10) 中谷佳博, ほか : 敗血症性ガス産生肝膿瘍の1例. 日本臨床外科医学会雑誌 57 : 145-149, 199. 6.
11) 迫川賢士, ほか : 腹腔鏡下に診断した門脈ガス血症とガス産生肝膿瘍を伴った胆嚢炎の1例. 日本臨床外科学会雑誌 77 : 607-613. 2016.
12) 久保智洋, ほか : 集学的治療により救命し得たClostridium Perfringensによる肝膿瘍の2例. 肝臓 58 : 105-114, 2017.
13) 加村毅 : 細菌性・アメーバ性肝膿瘍. 肝胆膵 49 : 849-852, 2004.
14) 蒲田敏文, 松井修 : 化膿性肝膿瘍 : 感染症, 細菌性肝疾患. 別冊日本臨床新領域別症候群シリーズ No. 13 肝・胆道系症候群 (第2版) I 肝臓編 (上), p70-75, 日本臨牀社, 2010.
15) 牛田進一郎, ほか : 膿瘍再発を繰り返したガス産生破裂性肝膿瘍の1例. 日本臨床外科学会雑誌 66 : 2787-2791, 2005.
P.62 掲載の参考文献
1) 松田肇, 桐木雅史 : 住血吸虫症の歴史と現状. 医学のあゆみ 208 : 74-78, 2004.
2) WHO : Schistosomiais. Fact sheets. [https://www.who.int/news-room/fact-sheets/detail/schistosomiasis]
3) Song LG, et al : History of schistosomiasis epidemiology, current status, and challenges in China : on the road to schistosomiasis elimination. Rarasitol Res 115 : 4071-4081, 2016.
4) Schistosomiasis : number of people treated worldwide in 2013. Wkly Epidemiol Rec 90 : 25-32, 2015.
5) 桐木雅史, ほか : 住血吸虫症. Dokkyo Journal of Medical Sciences 42 : 233-237, 2015.
6) Zheng B, et al : T Lymphocyte-Mediated Liver Immunopathology of Schistosomiasis. Front Immunol 11 : 61, 2020.
7) Barsoum RS, et al : Human schistosomiasis : clinical perspective : review. J Adv Res 4 : 433-444, 2013.
8) McManus DP, et al : Schistosomiasis. Nat Rev Dis Primers 4 : 13, 2018.
9) 大前比呂思, 千草雄一 : 肝住血吸虫症 ; 感染症, 肝寄生虫症. 別冊日本臨牀新領域別症候群シリーズ No. 13 肝・胆道系症候群 (第2版) I 肝臓編 (上), p98-102, 日本臨牀社, 2010.
10) Carvalho Santos J, et al : Liver ultrasound elastography for the evaluation of periportal fibrosis in schistosomiasis mansoni : A cross-sectional study. PLoS Negl Trop Dis 12 : e0006868, 2018.
11) Lucas SB, et al : Other viral and infectious diseases and HIV-related liver disease. In : MacSween's Pathology of the Liver (Sixth edition), p403-466, Churchill Livingstone, Elsevier, 2012.
P.68 掲載の参考文献
1) Schweiger A, et al : Human alveolar echinococcosis after fox population increase, Switzerland. Emerging Infect Dis 13 : 878-882, 2007.
2) 国立感染症研究所 : 病原微生物検出情報 (IASR) 40 : 33-48, 2019.
3) Wen H, et al : Echinococcosis : Advances in the 21st Century. Clin Microbiol Rev 32 : e00075-18, 2019.
4) Frider B, et al : Long-term outcome of asymptomatic liver hydatidosis. J Hepatol 30 : 228-231, 1999.
5) Nonaka N, et al : Echinococcus multilocularis infection in pet dogs in Japan. Vector Borne Zoonotic Dis 9 : 201-206, 2009.
6) Ito A, et al : Culinary delights and travel? A review of zoonotic cestodiases and metacestodiases. Travel Med Infect Dis 12 : 582-591, 2014.
7) 佐藤直樹, ほか : エキノコックス症. 肝胆膵 49 : 861-865, 2004.
8) Brunetti E, et al : Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 114 : 1-16, 2010.
9) Kodama Y, et al : Alveolar echinococcosis : MR findings in the liver. Radiology 228 : 172-177, 2003.
10) Reuter S, et al : Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 39 : 509-517, 2004.
11) Kern P, et al : WHO classification of alveolar echinococcosis : principles and application. Parasitol Int 55 Suppl : S283-287, 2006.
12) Lange H, et al : Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 34 : 315-317, 1988.
13) Junghanss T, et al : Clinical management of cystic echinococcosis : state of the art, problems, and perspectives. Am J Trop Med Hyg 79 : 301-311, 2008.
14) Ishizu H, et al : Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 25 : 528-531, 1997.
15) Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ 74 : 231-242, 1996.
P.71 掲載の参考文献
1) 川島哲也, ほか : 肝吸虫症. その他の感染症. 寄生虫症. 吸虫症. 別冊日本臨牀領域別症候群シリーズ 感染症症候群 II, p490-492, 1999.
2) 相野田隆雄 : 肝細胞癌・胆管癌と寄生虫. 医学のあゆみ 187 : 993-997, 1998.
3) 白井智之, 小川久美子 : 寄生虫と胆管細胞癌. 肝胆膵 37 : 173-179, 1998.
4) 松林潤, ほか : 肝吸虫症に合併した肝内胆管癌の1例. 日本消化器外科学会雑誌 48 : 328-336, 2015.
5) Thamavit W, et al : Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 38 : 4634-4639, 1978.
6) Thamavit W, et al : Level of Opisthorchis infestation and carcinogen dose-dependence of cholangiocarcinoma induction in Syrian golden hamsters. Virchows Archiv B Cell Pathol Incl Mol Pathol 54 : 52-58, 1987.
7) 迫裕孝, ほか : 肝吸虫症に合併した十二指腸乳頭部癌の1例. 外科 60 : 329-332, 1998.
8) 石川真, ほか : 肝吸虫症に合併した総胆管癌の1例. 日本臨床外科学会雑誌 59 : 2132-2135, 1998.
9) 小野寺滋, ほか : 十二指腸乳頭部癌を合併した肝吸虫症の1例-中国より帰化した女性で経験した-. 日本消化器病学会雑誌 104 : 213-218, 2007.
P.75 掲載の参考文献
1) Yoshida M, et al : A retrospective study of ocular toxocariasis in Japan : correlation with antibody prevalence and ophthalmological findings of patients with uveitis. J Helminthol 73 : 357-361, 1999.
3) 四倉正也, ほか : 肝内胆管癌との術前鑑別が困難であった内臓幼虫移行症の1例. 日本臨床外科学会雑誌 74 : 1655-1660, 2013.
4) 福谷洋樹, ほか : B型慢性肝炎患者に出現した肝トキソカラ症の1例. 日本消化器病学会雑誌 117 : 270-276, 2020.
5) 山本徳栄 : 食品媒介によるトキソカラ症. 日本食品微生物学会雑誌 31 : 1-12, 2014.
6) 宇賀昭二 : 公園砂場の糞便ならびにトキソカラ属線虫卵汚染状況-汚染の現状とその対策-. 環動昆 6 : 90-96, 1994.
7) 大島智夫 : イヌ回虫症およびネコ回虫症. 臨床医 16 : 318-322, 1990.
8) Beaver PC, et al : Chronic eosinophilia due to visceral larva migrans ; report of three cases. Pediatrics 9 : 7-19, 1952.
9) Dent AE, Kazura JW : Toxocariasis (Visceral and Ocular Larva Migrans). In : Nelson Textbook of Pediatrics, p1888-1889, Elsevier, Ameterdam, 2019.
10) Beaver PC : The nature of visceral larva migrans. J Parasitol 55 : 3-12, 1969.
11) Rayes A, et al : Visceral larva migrans syndrome complicated by liver abscess. Scand J Infect Dis 31 : 324-325, 1999.
12) 山下由美子, ほか : C型慢性肝炎治癒後に出現した肝トキソカラ症の1例. 肝臓 58 : 46-52, 2017.
13) Kakimoto M, et al : Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm. Intern Med 58 : 2737-2741, 2019.
14) Yoshida A, et al : Larva migrans syndrome caused by Toxocara and Ascaris roundworm infections in Japanese patients. Eur J Clin Microbiol Infect Dis 35 : 1521-1529, 2016.
15) 寄生虫症薬物治療の手引き-2020-改訂第10.2版 (日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業「わが国における熱帯病・寄生虫症の最適な診断治療予防体制の構築), p83-85, 2020.
P.80 掲載の参考文献
1) WHO : Foodborne trematode infections. [https://www.who.int/foodborne_trematode_infections/fascioliasis/en/]
2) CDC : Fascioliasis [https://www.cdc.gov/dpdx/fascioliasis/index.html]
3) 大島智夫 : 寄生虫と原虫による肝疾患. 日本臨牀 46 (増刊 : 肝胆疾患 (上)) : 824-833, 1988.
4) 影井昇 : 日本における人肝蛭症感染の現状 IASR Vol. 14 (1993/5 [159]).
5) Mas-Coma S, et al : Fascioliasis. Adv Exp Med Biol 1154 : 71-103, 2019.
6) Mas-Coma S : Human fascioliasis emergence risks in developed countries : From individual patients and small epidemics to climate and global change impacts. Enferm Infecc Microbiol Clin 38 : 253-256, 2020.
7) Fox NJ, et al : Predicting impacts of climate change on Fasciola hepatica risk. PLoS One 6 : e16126, 2011. [DOI : 10.1371/journal.pone.0016126]
8) Guo X, Guo A : Profiling circulating microRNAs in serum of Fasciola gigantica-infected buffalo. Mol Biochem Parasitol 232 : 111201, 2019.
9) Huang SY, et al : Development of a nest-PCR for detection of Fasciola hepatica DNA in the intermediate snail host, Radix cucunorica, and the prevalence in northwestern China. Infect Genet Evol 75 : 103984, 2019.
10) 佐藤雄生, 高坂佳宏 : FDG-PET CTにより悪性腫瘍が疑われた肝蛭症の1例. 日外科系連会誌 36 : 850-855, 2011.
11) Kaida T, et al : Inflammatory Liver Tumor Caused by Fasciola hepatica Mimicking Intrahepatic Cholangiocarcinoma. Anticancer Res 40 : 2795-2800, 2020.
12) Preza O, et al : Fascioliasis : A challenging differential diagnosis for radiologists. J Radiol Case Rep 13 : 11-16, 2019.
13) Gandhi P, et al : Triclabendazole in the treatment of human fascioliasis : a review. Trans R Soc Trop Med Hyg 113 : 797-804, 2019.
14) 中村 (内山) ふくみ : 不明熱と感染症 寄生虫疾患. 日内会誌 106 : 2373-2379, 2017.
P.84 掲載の参考文献
1) Stanley SL : Amoebiasis. Lancet 361 : 1025-1034, 2003.
2) Que X, Reed SL : Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev 13 : 196-206, 2000.
3) 重福隆太, ほか : 過去20年間における肝膿瘍153例の臨床的検討. 肝臓 59 : 466-480, 2018.
4) Escola-Verge L, et al : Outbreak of intestinal amoebiasis among men who have sex with men. Barcelona (Spain), October 2016 and January 2017. Euro Surveill 22 : 30581, 2017.
5) 国立感染症研究所 : アメーバ赤痢とは. IDWR 30, 2002. [https://www.niid.go.jp/niid/ja/kansennohanashi/315-amoeba-intro.html]
6) 国立感染症研究所 : アメーバ赤痢 2007年第1週~2016年第43週. IASR 37 : 239-240, 2016. [https://www.niid.go.jp/niid/ja/entamoeba-histolytica-m/entamoeba-histolytica-iasrtpc/6941-442t.html]
7) Keene WE, et al : The major neutral proteinase of Entamoeba histolytica. J Exp Med 163 : 536-549, 1986.
8) He C, et al : A Novel Entamoeba histolytica Cysteine Proteinase, EhCP4, is Key for Invasive Amebiasis and a Therapeutic Target. J Biol Chem 285 : 18516-185127, 2010.
9) Betanzos A, et al : The EhCPADH112 complex of Entamoeba histolytica interacts with tight junction proteins occludin and claudin-1 to produce epithelial damage. PLoS ONE 8 : e65100, 2013.
10) Shimokawa C, et al : Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis 206 : 744-751, 2012.
11) Douglas NM, et al : Use of a rapid faeces multiplex PCR assay for diagnosis of amoebic liver abscess. Pathology 52 : 725-727, 2020.
12) Cope JR, Ali IK : Amebiasis. Centers for Disease Control and Prevention (CDC), Chapter 4, Travel-Related Infectious Diseases, 2019. [https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/amebiasis]
13) 熱帯病治療薬研究班 : 寄生虫症薬物治療の手引き 改訂第10.2版, p8-12, 2020.
14) Kouzu K, et al : Successful surgical drainage with intraoperative ultrasonography for amebic liver abscess refractory to metronidazole and percutaneous drainage : a case report. BMC Surg 20 : 112, 2020.
15) 広瀬邦弘, ほか : Compromised hostに発症したアメーバ性肝膿瘍の1例. 日本臨床外科学会雑誌 74 : 998-1002, 2013.
P.89 掲載の参考文献
1) Fiore M, et al : Liver fungal infections : an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies. Infect Drug Resist 11 : 177-186. 2018.
3) Ekpanyapong S, Reddy KR : Fungal and Parasitic Infections of the Liver. Gastroenterol Clin North Am 49 : 379-410, 2020.
4) Cornely OA, et al : Hepatosplenic candidiasis. Clin Liver Dis (Hoboken) 6 : 47-50, 2015.
5) Kulaksiz H, et al : Biliary candida infections in primary sclerosing cholangitis. J Hepatol 45 : 711-716, 2006.
6) Pappas PG, et al : Clinical Practice Guideline for the Management of Candidiasis : 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 62 : e1-50, 2016.
7) 深在性真菌症の診断・治療ガイドライン 2014 小児領域改訂版 (深在性真菌症のガイドライン作成委員会編), 協和企画, 2016.
8) Patel GP, et al : The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 16 : 508-511, 2009.
10) Patterson TF, et al : Practice Guidelines for the Diagnosis and Management of Aspergillosis : 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63 : e1-e60, 2016.
11) Pagano L, et al : Fungal infections in recipients of hematopoietic stem cell transplants : results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45 : 1161-1170, 2007.
12) Shukla S, et al : Liver dysfunction as the presenting feature of disseminated cryptococcosis. Southern African Journal of Infectious Diseases 31 : 38-40, 2016.
13) 鈴木俊幸, ほか : ATLに合併した肝クリプトコッカス症の1例. 日本消化器病学会雑誌 112 : 2168-2175, 2015.
14) Sun D, et al : Fungal dissemination is limited by liver macrophage filtration of the blood. Nat Commun 10 : 4566, 2019.
15) Perfect JR, et al : Clinical practice guidelines for the management of cryptococcal disease : 2010 update by the infectious diseases society of america. Clin Infect Dis 50 : 291-322, 2010.
P.94 掲載の参考文献
1) 厚生労働省ホームページ : 感染症法に基づく医師の届出のお願い 43レプトスピラ症. [https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-04-40.html]
2) NIID国立感染症研究所ホームページ : レプトスピラ症とは. [https://www.niid.go.jp/niid/ja/kansennohanashi/531-leptospirosis.html]
3) NIID国立感染症研究所ホームページ : レプトスピラ症 2007年1月~2016年4月. IASR 37 : 103-105, 2016. [https://www.niid.go.jp/niid/ja/leptospirosis-m/leptospirosis-iasrtpc/6518-436t.html]
4) 坂本光男, ほか : マレーシア, ボルネオ島で感染したレプトスピラ症の1例. 感染症学雑誌 75 : 1057-1061, 2001.
5) NIID国立感染症研究所ホームページ : 日本の輸入感染症例の動向について. [https://www.niid.go.jp/niid/ja/route/transport/1709-idsc/8045-imported-cases.html]
6) 福田竜基, ほか : 肝レプトスピラ症, Weil病 ; 感染症. その他の感染症. 別冊日本臨牀新領域別症候群シリーズ NO. 13 肝・胆道系症候群 (第2版) I 肝臓編 (上), p149-153, 日本臨牀社, 2010.
7) Human leptospirosis : guidance for diagnosis, surveillance and contr ol (ed by World Health Organization), p1-107, WHO Library, 2003.
8) Levett PN, Haake DA : Leptospira species (Leptospirosis). In : Principles and Practice of Infectious Diseases, 7th ed (ed by Mandell GL, et al), p3059-3065, Churchill Livingstone, Elsevier, Philadelphia, 2009.
9) Kahloun R, et al : Infectious optic neuropathies : a clinical update. Eye Brain 7 : 59-81, 2015.
11) Haake DA, Levett PN : Leptospirosis in humans. Curr Top Microbiol Immunol 387 : 65-97, 2015.
12) Taylor AJ, et al : A systematic review of the mortality from untreated Leptospirosis. PLoS Negl Trop Dis 9 : e0003866, 2015.
P.98 掲載の参考文献
2) 佐藤保則, ほか : 感染症と肉芽腫 : 結核症. Visceral larva migrans, 免疫不全症と肉芽腫性疾患, その他の感染症 (真菌症, 寄生虫性疾患を含む). 肝胆膵 57 : 577-583, 2008.
3) 公益財団法人結核予防会結核研究所疫学情報センター. [http://www.jata.or.jp/rit/ekigaku/]
4) 関谷千尋, 幸田弘信 : 細菌感染症と肝 (4) 結核と肝. 臨牀消化器内科 16 : 455-460, 2001.
5) 独立行政法人医薬品医療機器総合機構. 抗PD-1抗体医薬品の「使用上の注意」の改訂について, 2019. [https://www.pmda.go.jp/files/000229827.pdf]
6) 厚生労働省 : 薬生案発0604第1号. 令和元年6月4日 「使用上の注意」の改訂について. [https://www.mhlw.go.jp/hourei/doc/tsuchi/T19060510020.pdf]
7) Kawmura I : [The control by Mycobacterium tuberculosis of the expression of host resistance to infection]. Kekkaku 88 : 315-321, 2013.
8) Gandhi NM, et al : Bacillus Calmette-Guerin immunotherapy f or genitourinary cancer. BJU Int 112 : 288-297, 2013.
9) 恵荘裕嗣, ほか : 播種性bacillus Calmette-Guerin (BCG) 症に随伴したgranulomatous hepatitisの2例. 肝臓 58 : 406-414, 2017.
10) 杤谷四科子, ほか : 結核菌PCR陽性により診断し. 保存的に加療した孤立性肝結核腫の1例. 日本消化器病学会雑誌 110 : 669-678, 2013.
11) 三石雄大, ほか : 肝多発腫瘤性病変を呈し, 抗結核薬が著効した肝結核の1例. 肝臓 55 : 40-50, 2014.
12) 小田桂子, ほか : キノロン系抗菌薬投与により診断が遅延し肝生検・骨髄生検にて粟粒結核と診断しえた糖尿病患者の1例. 糖尿病 58 : 902-907, 2015.
13) 岡本欣也, ほか : B型肝炎ウイルスキャリアに発症し肝細胞癌との鑑別に苦慮した孤立性肝結核腫の1例. 肝臓 44 : 448-454. 2003.
14) 日本結核病学会教育委員会 : 結核の診断 : 結核症の基礎知識 (改訂第4版). 結核 89 : 521-545, 2014.
15) 日本結核病学会治療委員会 : 「結核医療の基準」の改訂-2018年. 結核 93 : 61-68, 2018.
16) 村上正巳, ほか : バセドウ病の治療開始後発熱と肝機能障害で発症し診断が困難であった肝結核の一例. 日本内分泌学会雑誌 76 : 127-130, 2000.
P.102 掲載の参考文献
1) Hahn RD : Syphilis of the liver. Am J Syph Gnorrhea Vener Dis 27 : 529-562, 1943.
2) Feher J, et al : Early syphilitic hepatitis. Lancet 2 : 896-899, 1975.
3) 行本敦, ほか : 早期梅毒性急性肝炎の1例. 日本内科学会雑誌 107 : 1095-1101, 2018.
4) Huang J, et al : A Systematic Literature Review of Syphilitic Hepatitis in Adults. J Clin Transl Hepatol 6 : 306-309, 2018.
5) 中西満, ほか : 著明な肝実質障害を伴った早期梅毒性肝炎の1例. 肝臓 41 : 759-763, 2000.
6) 大野彰久, ほか : 皮疹の増悪を契機に診断しえた早期梅毒性肝炎の一例. 肝臓 57 : 481-486, 2016.
7) 谷口彰治, ほか : 地帯現象 (prozone phenomenon) を認めた第2期梅毒. 皮膚 6 : 821-824. 1994.
8) Centers for Disease Control and Prevention : Workowski KA, et al : Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64 (RR-03) : 1-137, 2015.
9) 性感染症 診断・治療ガイドライン 2016. 日本性感染症学会誌 27 (1 Suppl) : 1-176, 2016

II 生活習慣による肝疾患

P.109 掲載の参考文献
1) Musso G, et al : Meta-analysis : natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 : 617-649, 2011.
2) NASH・NAFLDの診療ガイド 2015 (日本肝臓学会編), 文光堂, 2015.
3) Eslam M, et al : MAFLD : A Consensus-Driven Prop osed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 158 : 1999-2014.e1, 2020.
5) Higuchi S, et al : Japan : alcohol today. Addiction 102 : 1849-1862, 2007.
7) 山本匡介 : 脂肪肝の生化学, インスリン抵抗性. 肝臓 45 : 66-70, 2004.
8) Takeuchi Y, et al : KLF15 Enables Rapid Switching between Lipogenesis and Gluconeogenesis during Fasting. Cell Rep 16 : 2373-2386, 2016.
10) Tian C, et al : Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42 : 21-23, 2010.
P.114 掲載の参考文献
1) Chalasani N, et al : The diagnosis and management of non-alcoholic fatty liver disease : practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 : 2005-2023, 2012.
3) Koda M, et al : The impact of visceral fat in nonalcoholic fatty liver disease : cross-sectional and longitudinal studies. J Gastroenterol 42 : 897-903, 2007.
4) Kojima H, et al : Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 31 : S61-66, 2007.
5) Nishioji K, et al : Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol 50 : 95-108, 2015.
6) Karlas T, et al : Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66 : 1022-1030, 2017.
7) Huang MA, et al : One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis : a pilot study. Am J Gastroenterol 100 : 1072-1081, 2005.
8) Toshimitsu K, et al : Changes of anthropometric and biological parameters in patients with non-alcoholic steatohepetitis for dietary modification. J Metab Clin Nutr 12 : 337-346, 2009.
9) Johnson NA, et al : Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50 : 1105-1112, 2009.
10) Sumida Y, et al : Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease : A prospective, single-arm trial (LEAD trial). Hepatol Res 49 : 64-71, 2019.
P.118 掲載の参考文献
1) Ludwig J, et al : Nonalcoholic steεltohepatitis : Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 : 434-438, 1980.
2) Schaffner F : Non-alcoholic fatty liver. In : Bockus Gastroenterology, 4th ed (ed by Berk JE, et al), p3049-3061, Saunders, Philadelphia, 1985.
3) NAFLD/NASH診療ガイドライン 2014 (日本消化器病学会編), 南江堂, 2014.
4) Eguchi Y, et al ; JSG-NAFLD : Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan : multicenter large retrospective study. J Gastroenetrol 47 : 586-595, 2012.
6) Younossi ZM, et al : Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 : 73-84, 2016.
7) NASH・NAFLDの診療ガイド 2015 (日本肝臓学会編), 文光堂, 2015.
P.123 掲載の参考文献
1) アルコール性肝障害診断基準 2011年版 (アルコール医学生物学研究会編), 響文社, 2012.
2) Louvet A, et al : Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology 155 : 458-468. e8, 2018.
P.128 掲載の参考文献
1) JASBRAアルコール性肝障害診断基準 (2011年版) (日本アルコール医学生物学研究会編), 2012.
2) Sozio M, Crabb DW : Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab 295 : E10-16, 2008.
3) Longato L, et al : Insulin resistance, ceramide accumulation, and endoplasmlc retlculum stress In human chronic alcohol-related liver disease. Oxid Med Cell Longev 2012 : 479348, 2012.
5) Wang Z, et al : Chronic alcohol consumption disrupted cholesterol homeostasis in rats : down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res 34 : 471-478, 2010.
6) Fujita K, et al : Novel findings for the development of drug therapy for various liver diseases : Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. J Pharmacol Sci 115 : 270-273, 2011.
7) 中牟田誠 : 生活習慣と脂肪肝. 日本消化器病学会雑誌 117 : 375-383, 2020.
8) Crabb DW, et al : Diagnosis and Treatment of Alcohol-Associated Liver Diseases : 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71 : 306-333, 2020.
9) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Management of alcohol-related liver disease. J Hepatol 69 : 154-181, 2018.
P.132 掲載の参考文献
1) Nakayama N, et al : A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 48 : 303-312, 2018.
2) Moreau R, et al : Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144 : 1426-1437, 1437.e1-9, 2013.
3) Basra S, Anand BS : Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol 3 : 108-113, 2011.
4) Yang AL, et al : Epidemiology of alcohol-related liver and pancreatic disease in the United States. Arch Intern Med 168 : 649-656, 2008.
5) 厚生労働省大臣官房統計情報部 : 平成29年患者調査 (傷病分類編), 2019年3月1日.
6) Dugum M, McCullough A : Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol 3 : 109-116, 2015.
7) JASBRAアルコール性肝障害診断基準 (2011年版) (日本アルコール医学生物学研究会編 (JASBRA)), 2012.
8) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Management of alcohol-related liver disease. J Hepatol 69 : 154-181, 2018.
9) Crabb DW, et al : Diagnosis and Treatment of Alcohol-Associated Liver Diseases : 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71 : 306-333, 2020.
10) McClain C, et al : Role of Zinc in the Development/Progression of Alcoholic Liver Disease. Curr Treat Options Gastroenterol 15 : 285-295, 2017.
11) Lieber SR, et al : Controversies in clinical trials for alcoholic hepatitis. J Hepatol 68 : 586-592, 2018.
12) Thursz MR, et al : Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 372 : 1619-1628, 2015.
13) Nguyen-Khac E, et al : Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 365 : 1781-1789, 2011.
14) Singh S, et al : Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis : A Systematic Review and Network Meta-analysis. Gastroenterology 149 : 958-970.e12, 2015.
15) Horie Y, et al : Therapeutic strategies for severe alcoholic hepatitis. Clin Res Hepatol Gastroenterol 35 : 738-744, 2011.
16) 堀江義則, ほか : 本邦におけるアルコール性肝炎の現状-全国アンケート調査報告 (2012年度) -. 肝臓 57 : 171-177, 2016.
P.137 掲載の参考文献
1) 酒井輝文, ほか : まだら脂肪肝の超音波像. 日超医論文集 41 : 75-76, 1982.
2) 広岡昇, 大藤正雄 : 不規則脂肪肝. 肝胆膵 16 : 947-951, 1988.
3) 大類方巳, ほか : 人間ドックにおけるまだら脂肪肝の検討. 日本人間ドック学会誌 7 : 50-54, 1992.
4) Brawer MK, et al : Focal fatty change of the liver, a hitherto poorly recognized entity. Gastroenterology 78 : 247-252, 1980.
6) Decarie PO, et al : Fatty liver deposition and sparing : a pictorial review. Insights Imaging 2 : 533-538, 2011.
7) Hamer OW, et al : Fatty liver : imaging patterns and pitfalls. Radiographics 26 : 1637-1653, 2006.
8) Jang JK, et al : Focal fat deposition in the liver : diagnostic challenges on imaging. Abdom Radiol (NY) 42 : 1667-1678, 2017.
9) Bonekamp S, et al : Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging 39 : 1525-1532, 2014.
10) Vu KN, et al : MRI-determined liver proton density fat fraction, with MRS validation : Comparison of regions of interest sampling methods in patients with type 2 diabetes. J Magn Reson Imaging 43 : 1090-1099, 2016.
11) Dioguardi Burgio M, et al : The cheating liver : imaging of focal steatosis and fatty sparing. Expert Rev Gastroenterol Hepatol 10 : 671-678, 2016.
12) Imajo K, et al : Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 150 : 626-637.e7, 2016.
13) Yoneda M, et al : Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 56 : 1330-1331, 2007.
14) Sasso M, et al : Controlled attenuation parameter (CAP) : a novel VCTE(TM) guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36 : 1825-1835, 2010.
15) Karlas T, et al : Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66 : 1022-1030, 2017.
P.142 掲載の参考文献
2) Nakahara T, et al : Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 49 : 1477-1484, 2014.
3) Ludwig J, et al : Nonalcoholic steatohepatitis : Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 55 : 434-438, 1980.
5) Jimba S, et al : Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22 : 1141-1145, 2005.
6) Seko Y, et al : Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatol Res 48 : E42-E51, 2018.
7) Fujii H, et al : HOMA-IR : An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol 34 : 1390-1395, 2019.
10) 添田光太郎, 植木浩二郎 : 糖尿病とNASH・NAFLD. 臨牀消化器内科 33 : 45-52, 2018.
11) Hosooka T, et al : The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis. Proc Natl Acad Sic USA 117 : 11674-11684, 2020.
13) Leiter LA, et al : Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42 : 25-32, 2016.
14) Seko Y, et al : Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type2 diabetes mellitus : pooled and subgroup analyses of clinical trials. J Gastroenterol 53 : 140-151, 2018.
15) Armstrong MJ, et al : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 : 679-690, 2016.
16) Seko Y, et al : Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47 : 1206-1211, 2017.
P.147 掲載の参考文献
1) Williams CD : Kwashiorkor. A nutritional disease of children associated with a maize diet. The Lancet 226 : 1151-1152, 1935.
2) Benjamin O, Lappin SL : Kwashiorkor. Stat Pearls Publishing, 2020.
3) Sha W, et al : Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J 24 : 2962-2975, 2010.
4) Noga AA, Vance DE : Insights into the requirement of phosphatidylcholine synthesis for liver function in mice. J Lipid Res 44 : 1998-2005, 2003.
5) 樋口佳莉子, ほか : Crohn病の経過中に非アルコール性脂肪肝から肝硬変に進展した1例. 肝臓 49 : 368-375. 2008.
6) Paquot N, Delwaide J : Fatty liver in the intensive care unit. Curr Opin Clin Nutr Metab Care 8 : 183-187, 2005.
7) Tanaka N, et al : Pancreatic exocrine insufficiency : a rare cause of nonalcoholic steatohepatitis. Am J Gastroenterol 103 : 245-246, 2008.
8) Tanaka N, et al : Clinical characteristics of de novo nonalcoholic fatty live disease following pancreaticoduodenectomy. J Gastroenterol 46 : 758-768, 2011.
9) 渡邊利広, 木村理 : 膵頭十二指腸切除術後の合併症としてのNASH/NAFLD. 肝胆膵 76 : 569-575, 2018.
10) 加藤宏之, ほか : 膵切除後の消化吸収障害と低栄養, 脂肪肝について. 膵臓 34 : 157-165, 2019.
11) Sakada M, et al : Severe steatosis resulted from anorexia nervosa leading to fatal hepatic failure. J Gastroenterol 41 : 714-715, 2006.
12) 寺田光宏, ほか : 神経因性食欲不振症の経過中, 著明な肝腫大を呈し, 肝不全にて死亡したnonalcoholic steatohepatitisの1例. 肝臓 38 : 617-621, 1997.
13) 松村真生子, ほか : アルコール性肝炎, 肝不全との鑑別を要したkwashiorkor型栄養障害の1例. 肝臓 54 : 178-186, 2013.
14) Young S, et al : Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults : Systematic Review and Meta-Analysis. Hepatol Commun 4 : 953-972, 2020.
15) Azuma K, et al : Higher liver fat content among Japanese in Japan compared with non-Hispanic whites in the United States. Metab Clin Exp 58 : 1200-1207, 2009.

III 自己免疫性肝疾患

P.154 掲載の参考文献
1) Krawitt EL : Autoimmune hepatitis. N Engl J Med 354 : 54-66, 2006.
2) de Boer YS, et al : Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147 : 443-452. e5, 2014.
4) Christen U, Hintermann E : Immunopathogenic Mechanisms of Autoimmune Hepatitis : How Much Do We Know from Animal Models? Int J Mol Sci 17 : 2007, 2016.
5) Onji M, et al : Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 41 : 497, 2011.
6) Harada K : Histological findings of autoimmune hepatitis. In : Autoimmune Liver Diseases, Perspectives from Japan (ed by Ohira H), p45-65, Springer, Tokyo, 2014.
7) 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班 : 自己免疫性肝炎 (AIH) 診療ガイドライン (2016年) Ver 3, 2020年1月.
8) Alvarez F, et al : International Autoimmune Hepatitis Group Report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 : 929-938, 1999.
10) Takahashi A, et al : Rapid corticosteroid tapering : Important risk factor for type 1 autoimmune hepatitis relapse in Japan. Hepatol Res 45 : 638-644, 2015.
12) Kakuta Y, et al : NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol 53 : 1065-1078, 2018.
13) Abe K, et al : Clinical features of cirrhosis in Japanese patients with type 1 autoimmune hepatitis. Intern Med 51 : 3323-3328, 2012.
Tanaka A, et al : Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 49 : 881-889, 2019.
P.158 掲載の参考文献
1) 田中篤, ほか : PBCの病名変更 : 「原発性胆汁性肝硬変」から「原発性胆汁性胆管炎」へ. 肝臓 57 : 309-311, 2016.
2) 厚生労働省難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究」班 : 原発性胆汁性胆管炎 (PBC) 診療ガイドライン (2017年).
3) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67 : 145-172, 2017.
4) Nakano T, et al : Long-term prognosis of primary biliary cirrhos is (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res 22 : 250-260, 2002.
5) Corpechot C, et al : Early primary biliary cirrhosis : biochemical response to treatment and prediction of long-term outcome. J Hepatol 55 : 1361-1367, 2011.
7) Corpechot C, et al : A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 378 : 2171-2181, 2018.
8) Honda A, et al : Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology 70 : 2035-2046, 2019.
9) Yagi M, et al : Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol 53 : 1151-1158, 2018.
10) Singal AK, et al : Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95 : 755-760, 2013.
11) Adam R, et al : Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57 : 675-688, 2012.
12) Harada K, et al : Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis : national data from Japan. Hepatology 57 : 1942-1949, 2013.
P.163 掲載の参考文献
1) Corpechot C, et al : Primary biliary cirrhosis : incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122 : 652-658, 2002.
3) Kobayashi M, et al : Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 20 : 3597-3608, 2014.
4) Zhang W, et al : New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun 2 : 245-253, 2018.
5) Verdonk RC, et al : Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int 36 : 1362-1369, 2016.
7) Freedman BL, et al : Treatment of Overlap Syndromes in Autoimmune Liver Disease : A Systematic Review and Meta-Analysis. J Clin Med 9 : 1449, 2020.
8) Boberg KM, et al : Overlap syndromes : the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 54 : 374-385, 2011.
P.168 掲載の参考文献
1) Eksteen B, et al : Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 200 : 1511-1517, 2004.
7) Tabibian JH, et al : Randomised clinical trial : vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 37 : 604-612, 2013.
8) Allegretti JR, et al : Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis : A Pilot Clinical Trial. Am J Gastroenterol 114 : 1071-1079, 2019.
10) Rabinovitz M, et al : Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 11 : 7-11, 1990.
11) Weismuller TJ, et al : Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 152 : 1975-1984.e8, 2017.
13) Navaneethan U, et al : The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 35 : 1045-1053, 2012.
14) Marelli L, et al : Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 60 : 1224-1228, 2011.
15) Lindor KD : Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 : 691-695, 1997.
17) Mizuno S, et al : Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 22 : 766-770, 2015,
18) Egawa H, et al : Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant 11 : 518-527, 2011.
19) de Vries EM, et al : Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later : evaluation of prognostic value. Liver Int 36 : 1867-1875, 2016.
P.172 掲載の参考文献
2) Masamune A, et al : Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol 55 : 462-470, 2020.
3) Tanaka A, et al : Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis. Clin Gastroenterol Hepatol 15 : 920-926.e3, 2017.
4) Kawa S, et al : HLA DRB1*0405-DQB1*0401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 122 : 1264-1269, 2002.
5) Hubers LM, et al : Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 67 : 728-735, 2018.
6) Shiokawa M, et al : Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med 10 : 2018.
7) Perugino CA, et al : Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol 143 : 736-745.e6, 2019.
8) 岡崎和一, ほか : IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道 26 : 59-63, 2012.
9) Ohara H, et al : Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis : a Japanese cohort. J Gastroenterol Hepatol 28 : 1247-1251, 2013.
11) 神澤輝実, ほか : IgG4関連硬化性胆管炎診療ガイドライン. 胆道 33 : 169-210, 2019.

IV 薬物性肝障害

P.181 掲載の参考文献
1) Aiso M, et al : Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res 49 : 105-110, 2019,
2) 為田靱彦, ほか : 薬剤性肝障害の全国集計. 最新肝臓病学 (渡辺明治, 樋口清博編), p50-61, 新興医学出版社, 2001.
3) 堀池典生, ほか : 薬物性肝障害の実態-全国調査-. 薬物性肝障害の実態 (恩地森一監修), p1-10, 中外医学社, 2008.
5) 滝川一, ほか : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
P.186 掲載の参考文献
1) Galan MV, et al : The burden of acute nonfluminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 39 : 64-67, 2005. Erratum in : J Clin Gastroenterol 39, 176, 2005.
3) Lucena MI, et al : Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry : the dilemma of the relationship to autoimmune hepatitis. J Hepatol 55 : 820-827, 2011.
4) Lammert C, et al : Relationship between daily dose of oral medications and idiosyncratic druginduced liver injury : search for signals. Hepatology 47 : 2003-2009, 2008.
5) Fontana RJ, et al : Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol 110 : 1450-1459, 2015.
6) Jetter A, Kullak Ublick GA : Drugs and hepatic transporters : A review. Pharmacol Res 154 : 104234, 2020.
7) Sundaram V, Bjornsson ES : Drug-induced cholestasis. Hepatol Commun 1 : 726-735, 2017.
8) 滝川一, ほか : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 86-90, 2005.
9) Paumgartner G, Beuers U : Ursodeoxycholic acid in cholestatic liver disease : mechanisms of action and therapeutic use revisited. Hepatology 36 : S25-37, 2002.
10) Beuers U, et al : New paradigm in the treatment of hepatic cholestasis : from UDCA to FXR, PXR and beyond. J Hepatol 62 (1 Suppl) : 525-537, 2015.
11) Festi D, et al : Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2 : 155-177, 2007.
12) Bonkovsky HL, et al : Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 65 : 1267-1277, 2017.
13) Ahmad J, et al : Drug induced liver injury associated with sclerosing cholangitis like changes on magnetic resonance cholangiography imaging. Hepatology 64 : 65A, 2016.
P.191 掲載の参考文献
2) Grieco A, et al : Fatty liver and drugs. Eur Rev Med Pharmacol Sci 9 : 261-263, 2005.
3) Amacher DE, Chalasani N : Drug-induced hepatic steatosis. Semin Liver Dis 34 : 205-214, 2014.
4) Mattar W, et al : Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis 18 : 419-423, 2009.
5) Langman G, et al : Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16 : 1395-1401, 2001.
6) Lindsay K, Gough A : Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk? Rheumatology (Oxford) 47 : 939-941, 2008.
7) Luef G, et al : Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 86 : 42-47, 2009.
8) Saphner T, et al : The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 115 : 3189-3195, 2009.
9) Bruno S, et al : Incidence and risk factors for non-alcoholic steatohepatitis : prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330 : 932, 2005.
10) Brouquet A, et al : Risk factors for chemotherapy-associated liver injuries : A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 145 : 362-371, 2009.
11) Miyake K, et al : Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 12 : 722-727, 2005.
12) Wolf PS, et al : Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer : a single institution experience. J Am Coll Surg 216 : 41-49, 2013.
13) Satapathy SK, et al : Drug-induced fatty liver disease : An overview of pathogenesis and management. Ann Hepatol 14 : 789-806, 2015.
P.196 掲載の参考文献
2) Schwingel PA, et al : Anabolic-androgenic steroids : a possible new risk factor of toxicant-associated fatty liver disease. Liver Int 31 : 348-353, 2011.
3) Doherty RE : A History of the Production and Use of Carbon Tetrachloride, Tetrachloroethylene, Trichloroethylene and 1, 1, 1-Trichloroethane in the United States : Part 1-Historical Background ; Carbon Tetrachloride and Tetrachloroethylene. Environ Forensics 1 : 69-81, 2000.
4) Seifert WF, et al : Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats. Hepatology 19 : 193-201, 1994.
5) 田中直樹, 青山俊文 : 化学物質による脂肪肝 ; アルコール性肝障害, NASH (非アルコール性脂肪肝炎) ・NAFLD (非アルコール性脂肪性肝疾患). 別冊日本臨床新領域別症候群シリーズ No. 13 肝・胆道系症候群 (第2版) I 肝臓編 (上), p196-201, 日本臨牀社, 2010.
6) Edwards MJ, et al : The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol Appl Pharmacol 119 : 275-279, 1993.
7) Wahlang B, et al : Toxicant-associated steatohepatitis. Toxicol Pathol 41 : 343-360, 2013.
8) Chen L, et al : Vinyl chloride-induced interaction of nonalcoholic and toxicant-associated steatohepatitis : Protection by the ALDH2 activator Alda-1. Redox Biol 24 : 101205, 2019.
9) Kennedy GL : Biological effects of acetamide, formamide, and their mono and dimethyl derivatives : an update. Crit Rev Toxicol 31 : 139-222, 2001.
10) Su TC, et al : Dimethylacetamide, ethylenediamine, and diphenylmethane diisocyanate poisoning manifest as acute psychosis and pulmonary edema : treatment with hemoperfusion. J Toxicol Clin Toxicol 38 : 429-433, 2000.
11) Brodkin CA, et al : Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 52 : 679-685, 1995.
12) Philip BK, et al : Impact of repeated exposure on toxicity of perchloroethylene in Swiss Webster mice. Toxicology 232 : 1-14, 2007.
13) Liu J : Clinical analysis of seven cases of trichloroethylene medicamentose-like dermatitis. Ind Health 47 : 685-688, 2009.
14) Ramdhan DH, et al : Differential response to trichloroethylene-induced hepatosteatosis in wild-type and PPARalpha-humanized mice. Environ Health Perspect 118 : 1557-1563, 2010.
15) Wang JD, et al : Dimethylformamide-induced liver damage among synthetic leather workers. Arch Environ Health 46 : 161-166, 1991.
16) Redlich CA, et al : Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. Gastroenterology 99 : 748-757, 1990.
P.200 掲載の参考文献
1) トロトラストによる放射線の晩発障害. [https://atomica.jaea.go.jp/data/detail/dat_detail_09-03-01-11.html]
2) 森田穣 : IVRの歩んできた道, 進む道. IVR会誌 JSIR 23 : 285-299, 2008.
3) Yamamoto Y, et al : Histological type of Thorotrast-induced liver tumors associated with the translocation of deposited radionuclides. Cancer Sci 101 : 336-340, 2010.
4) Becker N, et al : Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study. Eur J Cancer 44 : 1259-1268, 2008.
5) Wohlwill F : Untersuchungen uber die Gewebesreaktion auf Thorotrast bei Anwendung dieser Substanz zu diagnostischen Zwecken am Menschen. Schweizerische Zeitschrift fur allgemeine Pathologie und Bakeriologie 5 : 25-52, 1942.
6) Kato I, Kido C : Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn J Cancer Res 78 : 1187-1192, 1987.
7) Van Kaick G, et al : Neoplastic diseases induced by chronic alpha-irradiation-epidemiological, biophysical and clinical results of the German Thorotrast study. J Radiat Res 32 : S20-S33, 1991.
8) Ahmed J, Laurence J : Role of platelet-derived transforming growth factor-β1 and reactive oxygen species in radiation-induced organ fibrosis. Antioxid Redox Signal 27 : 977-988, 2017.
9) Cheng W, et al : Molecular responses of radiation-induced liver damage in rats. Mol Med Rep 11 : 2592-2600, 2015.
10) Sharp GB : The relationship between internally deposited alpha-particle radiation and subsite-specific liver cancer and liver cirrhosis : an analysis of published data. J Radiat Res 43 : 371-380, 2002.
11) Taylor JA, et al : p53 mutation hotspot in radon-associated lung cancer. Lancet 343 : 86-87, 1994.
12) Hollstein M, et al : p53 gene mutation analysis in tumors of patients exposed to alpha-particles. Carcinogenesis 18 : 511-516, 1997.
14) Liu D, et al : Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma. Int J Cancer 102 : 366-371, 2002.

V 肝不全

P.209 掲載の参考文献
1) Trey C, et al : Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med 279 : 798-801, 1968.
2) Mochida S : [Nationwide survey of acute liver failure according to the definition and classification in Japan]. Nihon Shokakibyo Gakkai Zasshi 112 : 813-821, 2015.
5) Kakisaka K, et al : Unfavorable prognosis of patients with acute liver injury due to drug-induced liver injury and acute exacerbation of hepatitis B virus infection. Hepatol Res 49 : 1286-1293, 2019.
6) Kakisaka K, et al : Predictive formula of coma onset and prothrombin time to distinguish patients who recover from acute liver injury. J Gastroenterol Hepatol 33 : 277-282, 2018.
7) Zarrin A, Akhondi H : Viral Hepatitis. Stat Pearls, Treasure Island (FL), 2020.
8) Lammert C, et al : Management of Difficult Cases of Autoimmune Hepatitis. Curr Gastroenterol Rep 18 : 9, 2016.
9) Kleiner DE, et al : Hepatic histological findings in suspected drug-induced liver injury : systematic evaluation and clinical associations. Hepatology 59 : 661-670, 2014.
10) Begriche K, et al : Drug-induced toxicity on mitochondria and lipid metabolism : mechanistic diversity and deleterious consequences for the liver. J Hepatol 54 : 773-794, 2011.
11) Kakisaka K, et al : Necrotic cell death and suppression of T-cell immunity characterized acute liver failure due to drug-induced liver injury. Cytokine 86 : 21-28, 2016.
P.213 掲載の参考文献
1) Sherlock S : Diseases of the Liver and Biliary System, 6 ed, p107-115, Blackwell Scientific Publication, Oxford, 1981.
3) Jalan R, et al : Acute-on chronic liver failure. J Hepatol 57 : 1336-1348, 2012.
4) Nakayama N, et al : A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 48 : 303-312, 2018.
5) 持田智, ほか : 我が国におけるAcute-On-Chronic Liver Failure (ACLF) の診断基準 (案). 肝臓 59 : 155-161, 2018.
6) Mochida S, et al : Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res 48 : 219-224, 2018.
7) 持田智, ほか : 我が国におけるAcute on Chronic Liver Failure (ACLF) の全国調査 (2017~18年). 厚生労働省科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」総合研究報告書, 2020.
8) 高田昭, ほか : アルコール性肝障害に対する新しい診断基準試案の提案. 肝臓 34 : 888-896, 1993.
9) Moreau R, et al : Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144 : 1426-1437, 1437.e1-9, 2013.
10) Zhang Q, et al : Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS ONE 10 : e0122158, 2015.
11) 持田智, ほか : 我が国における「急性肝不全」の概念, 診断基準の確立 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 : 393-398, 2011.
13) Watanabe K, et al : Sequential therapy consisting of glucocorticoid infusions followed by granulocyte-monocyte absorptive apheresis in patients with severe alcoholic hepatitis. J Gastroenterol 52 : 830-837, 2017.
14) Jalan R, et al : Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 61 : 1038-1047, 2014.
15) Choudhury A, et al : Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF) : comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int 11 : 461-471, 2017.
P.218 掲載の参考文献
1) 劇症肝炎の診断基準. A型肝炎, 劇症肝炎 : 第12回犬山シンポジウム (犬山シンポジウム記録刊行会編), p110-230, 中外医学社, 1982.
2) 持田智, ほか : 我が国における「急性肝不全」の概念, 診断基準の確立 : 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52 : 393-398, 2011.
5) Stravitz RT, Lee WM : Acute liver failure. Lancet 394 : 869-881, 2019.
6) Kaplowitz N : Mechanisms of liver cell injury. J Hepatol 32 : 39-47, 2000.
7) Mochida S, et al : Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 29 : 1532-1540, 1999.
10) Inoue J, et al : Analysis of the full-length genome of genotype 4 hepatitis E virus isolates from patients with fulminant or acute self-limited hepatitis E. J Med Virol 78 : 476-484, 2006.
12) Huh CG, et al : Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101 : 4477-4482, 2004.
13) Miwa Y, et al : Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure. J Hepatol 27 : 780-788, 1997.
14) Haussinger D, et al : Hepatic encephalopathy in chronic liver disease : a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32 : 1035-1038, 2000.
15) Naiki T, et al : Novel scoring system as a useful model to predict the outcome of patients with acute liver failure : Application to indication criteria for liver transplantation. Hepatol Res 42 : 68-75, 2012.
P.223 掲載の参考文献
1) 持田智 : 急性肝不全-概念, 診断基準とわが国における実態-. 日本消化器病学会雑誌 112 : 813-821, 2015.
2) 渡辺崇夫, 日浅陽一 : 疫学と成因-近年の肝硬変の成因の実態-. 最新医学別冊 診断と治療のABC Vol. 131 肝硬変 (坂井田功編), p27-34, 最新医学社, 2018,
3) Udell JA, et al : Does this patient with liver disease have cirrhosis? JAMA 307 : 832-842, 2012.
4) Boursier J, et al : Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 21 : 28-38, 2009.
5) Chou R, Wasson N : Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection : asystematic review. Ann Intern Med 158 : 807-820, 2013.
6) Yoon JH, et al : Hepatic fibrosis : prospective comparison of MR elastography and US shear-wave elastography for evaluation. Radiology 273 : 772-782, 2014.
7) Imajo K, et al : Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 150 : 626-637.e7, 2016.
8) 肝硬変診療ガイドライン 2015 (改訂第2版) (日本消化器病学会編), 南江堂, 2015.
9) Tsien CD, et al : Acute kidney injury in decompensated cirrhosis. Gut 62 : 131-137, 2013.
10) D'Amico G, et al : Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies. J Hepatol 44 : 217-231, 2006.
11) Chung H, et al : A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol Res 34 : 124-129, 2006.
12) Cholongitas E, et al : A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 12 : 1049-1061, 2006.
P.227 掲載の参考文献
1) 池田真美, ほか : 術後肝障害・肝不全. 消化器外科 (2020年4月増刊号) 43 : 878-880, 2020.
2) Kubo S, et al : Correlation between preoperative serum concentration of type IV collagen 7s domain and hepatic failure following resection of hepatocellular carcinoma. Ann Surg 239 : 186-193, 2004.
4) Tanaka S, et al : Preoperative risk assessment for loss of independence following hepatic resection in elderly patients : A prospective multicenter study. Ann Surg, 2019. (DOI : 10.1097/SLA.0000000000003585)
5) Nishio T, et al : Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. Surgery 159 : 399-408, 2016.
6) 久保正二, ほか : 肝切除後肝不全の病態と対策-硬変肝. 日本外科学会雑誌 105 : 669-673, 2004,
7) Kubo S, et al : Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 233 : 139-145, 2001.
8) Rahnemai-Azar AA, et al : Update on Liver Failure Following Hepatic Resection : Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6 : 97-104, 2018.
10) Johnson PJ, et al : Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol 33 : 550-558, 2015.
11) Kokudo T, et al : Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma-The Albumin-Indocyanine Green Evaluation (ALICE) Grade. PLoS ONE 11 : e0159530, 2016.
12) 幕内雅敏, ほか : 肝硬変合併肝癌治療のStrategy. 外科診療 29 : 1530-1536, 1987.
13) Okamoto E, et al : Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 95 : 586-592, 1984.
14) Kaibori M, et al : HA/GSA-Rmax ratio as a predictor of postoperative liver failure. World J Surg 32 : 2410-2418, 2008.
15) 河地茂行, ほか : 大腸癌肝転移-最新の治療ストラテジ-化学療法と肝障害. 臨床外科 71 : 404-408, 2016.
17) Shinkawa H, et al : Portal Vein Embolization : History and Current Indications. Visc Med 33 : 414-417, 2017.
18) de Santibafies E, et al : Playing Play-Doh to prevent postoperative liver failure : the "ALPPS" approach. Ann Surg 255 : 415-417, 2012.
19) Jin S, et al : Management of post-hepatectomy complications. World J Gastroenterol 19 : 7983-7991, 2013.
20) 伊神剛 : 消化管出血. 胆道外科の要点と盲点, 第2版 (幕内雅敏監, 二村雄次編), p432-435, 文光堂, 2009.

VI 血行異常

P.236 掲載の参考文献
1) 門脈圧亢進症取扱い規約 第3版 (日本門脈圧亢進症学会編), p20, 金原出版, 2013.
2) 門脈圧亢進症取扱い規約 第3版 (日本門脈圧亢進症学会編), p3-5, 金原出版, 2013.
3) 滝川一, ほか : 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version) (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班 ; 門脈血行異常症分科会), 2018.
4) DeLeve LD, et al : Vascular disorders of the liver. Hepatology 49 : 1729-1764, 2009.
5) 奥平雅彦 : 肝組織病変からみた肝硬変の病態. 日内会誌 80 : 1568-1571, 1991.
6) Di Marco V, et al : Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology 151 : 130-139.e2, 2016.
7) 國分茂博 : 門脈圧亢進症の現状と未来-本邦から海外に向けての発信-. 日消誌 116 : 363-373, 2019.
8) 肝硬変の成因別実態 2014 (泉並木監), p148, 医学図書出版, 2015.
9) Dignan FL, et al : BCSH/BSBMT guideline : diagnosis and management of veno-occlusive disease (Sinusoidal obstruction syndrome) following hematopoietic stem cell transplantation. Br J Haemotol 163 : 444-457, 2013.
10) Nakanuma Y, et al : Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 197 : 65-76, 2001.
11) Imajo K, et al : Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patient with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 : 623-637.e7, 2016.
12) Lens S, et al : Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology 153 : 1273-1283.e1, 2017.
13) Nedredal GI, et al : Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging 34 : 79-87, 2011.
14) Kokubu S : Treatment of portal vein thrombosis. In : Clinical Investigation of Portal Hypertension (ed by Obara K), p485-489, Springer, 2019.
15) Hidaka H, et al : Antithrombin III for portal vein thrombosis in patients with liver disease : A randomized, double blind, controlled trail. Hepatol Res 48 : E107-E116, 2018.
P.239 掲載の参考文献
1) Sarin SK, et al : Prevalence, classification and natural history of gastric varices : a long-term follow-up study in 568 portal hypertension patients. Hepatology 16 : 1343-1349, 1992.
2) Weiss B, et al : Etiology and long-term outcome of extrahepatic portal vein obstruction in children. World J Gastroenterol 16 : 4968-4972, 2010.
3) Webster GJ, et al : Review article : portal vein thrombosis-new insights into aetiology and management. Aliment Pharmacol Ther 21 : 1-9, 2005. (DOI : 10.1111/j.1365-2036.2004.02301.x)
4) di Francesco F, et al : Meso-Rex bypass-a procedure to cure prehepatic portal hypertension : the insight and the inside. J Am Coll Surg 218 : e23-36, 2014.
P.243 掲載の参考文献
1) de Franchis R, et al : Expanding consensus in portal hypertension : Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 : 743-752, 2015.
2) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症ガイドライン 2018年改訂版.
3) Hernandez-Gea V, et al : Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. J Hepatol 71 : 175-199, 2019.
4) Intagliata NM, et al : Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 156 : 1582-1599.e1, 2019.
5) Fan J, et al : Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis : A hospital-based observational study. J Gastroenterol Hepatol 35 : 1215-1222, 2020.
6) Khanna R, Sarin SK : Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int 12 : 148-167, 2018.
7) Valla DC : Recent developments in the field of vascular liver diseases. Liver Int 40 Suppl 1 : 142-148, 2020.
8) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Vascular diseases of the liver. J Hepatol 64 : 179-202, 2016.
9) Simonetto DA, et al : ACG Clinical Guideline : Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol 115 : 18-40, 2020.
10) Plessier A, et al : Acute portal vein thrombosis unrelated to cirrhosis : a prospective multicenter follow-up study. Hepatology 51 : 210-218, 2010.
11) Naymagon L et al : Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation. J Thromb Thrombolysis 50 : 652-660, 2020.
12) Ageno W, et al : Long-term Clinical Outcomes of Splanchnic Vein Thrombosis : Results of an International Registry. JAMA Intern Med 175 : 1474-1480, 2015.
13) Noronha Ferreira C, et al : Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 63 : 1640-1650, 2016.
14) Chen H, et al : Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction. J Gastroenterol Hepatol 35 : 1049-1056, 2020.
15) Sekimoto T, et al : Well-tolerated portal hypertension and favorable prognosis in adult patients with extrahepatic portal vein obstruction in Japan. Hepatol Res 46 : 505-513, 2016.
P.248 掲載の参考文献
1) DeLeve LD, et al : Vascular disorders of the liver. Hepatology 49 : 1729-1764, 2009.
2) Tsochatzis EA, et al : Systematic review : portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 31 : 366-374, 2010.
3) Intagliata NM, et al : Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 156 : 1582-1599.e1, 2019.
4) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Vascular diseases of the liver. J Hepatol 64 : 179-202, 2016.
5) Zocco MA, et al : Thrombotic risk factors in patients with liver cirrhosis : correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51 : 682-689, 2009.
6) Villa E, et al : Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143 : 1253-1260.e4, 2012.
7) Yerdel MA. et al : Portal vein thrombosis in adults undergoing liver transplantation : risk factors, screening, management, and outcome. Transplantation 69 : 1873-1881, 2000.
8) Misaki T, et al : Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery. J Orthop Sci 13 : 419-424, 2008.
9) Qi X, et al : Transient portal vein thrombosis in liver cirrhosis. BMC Med 16 : 83, 2018.
10) 門脈圧亢進症取扱い規約 第3版 (日本門脈圧亢進症学会編), 金原出版, 2013.
11) 山田涼子 : 肝硬変症例における門脈血栓症に対する治療戦略の現状. 肝胆膵 81 : 497-501, 2020.
12) Rodriguez-Castro KI, et al : A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 31 : 34-42, 2019.
13) Senzolo M, et al : Prospective evaluation of anticoagulation and transj ugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 32 : 919-927, 2012.
P.252 掲載の参考文献
1) 門脈圧亢進症取扱い規約 (第3版) (日本門脈圧亢進症学会編), 金原出版, 2013.
2) Garcia-Tsao G, et al : Portal hypertensive bleeding in cirrhosis : Risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65 : 310-335, 2017.
3) European Association for the Study of the Liver : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69 : 406-460, 2018.
4) de Franchis R, et al : Expanding consensus in portal hypertension : Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 : 743-752, 2015.
5) 門脈血行異常症ガイドライン 2018年改訂版 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班), p11-12, 2018.
6) 肝臓専門医テキスト 改訂第2版 (日本肝臓学会編), p463-464, 南江堂, 2016.
P.254 掲載の参考文献
2) Navasa M, et al : Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 5 : 292-298, 1987.
3) Maruyama H, et al : Retrograde detection of the intrahepatic portal vein in primary biliary cirrhosis : is sinusoidal blockage the underlying Pathophysiology? Eur J Gastroenterol Hepatol 27 : 321-327, 2015.
4) Ungprasert P, et al : Clinical Characteristics and Outcome of Hepatic Sarcoidosis : A Population-Based Study 1976-2013. Am J Gastroenterol 112 : 1556-1563, 2017.
5) Okuda K : Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 17 (Suppl 3) : S204-213, 2002.
6) 腹部エコーのABC (第2版) (日本医師会編・発行), 医学書院, 2004.
7) Farias AQ, et al : Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 24 : 1852-1856, 2009.
8) Sorensen M, et al : β-Blockers Improve Presinusoidal Portal Hypertension. Dig Dis Sci 63 : 3153-3157, 2018.
P.260 掲載の参考文献
1) 厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班 : 特発性門脈圧亢進症 (指定難病 92). 難病情報センターホームページ. [https://www.nanbyou.or.jp/entry/308]
2) Boyer JL, et al : Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med 66 : 41-68, 1967.
3) 厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班 : 門脈血行異常症ガイドライン 2018年改訂版. [http://www.hepatobiliary.jp/uploads/files/完成%E3%80%80門脈血行異常症ガイドライン大改訂版.pdf]
4) Sarin SK, et al : Noncirrhotic portal fibrosis/idiopathic portal hypertension : APASL recommen-dations for diagnosis and treatment. Hepatol Int 1 : 398-413, 2007.
5) Cazals-Hatem D, et al : Obliterative portal venopathy : portal hypertension is not always present at diagnosis. J Hepatol 54 : 455-461, 2011.
6) Mackie I, et al : Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 Deficiency. Dig Dis Sci 56 : 2456-2465, 2011.
7) Sato Y, et al : Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci 52 : 1987-1994, 2007.
8) Sato Y, et al : Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension : possible link to serum anti-endothelial cell antibodies. Clin Exp Immunol 167 : 532-542, 2012.
9) 井上博人, ほか : 特発性門脈圧亢進症 ; 肝動脈, 肝静脈, 門脈系異常. 別冊日本臨床新領域別症候群シリーズ No. 14 肝・胆道系症候群 (第2版) II 肝臓編 (下), p32-35, 日本臨牀社, 2010.
10) Sarin SK, et al : Familial aggregation in noncirrhotic portal fibrosis : a report of four families. Am J Gastroenterol 82 : 1130-1133, 1987.
11) Hernandez-Gea V. et al : Idiopathic Portal Hypertension. Hepatology 68 : 2413-2423, 2018.
12) Siramolpiwat S, et al : Idiopathic portal hypertension : natural history and long-term outcome. Hepatology 59 : 2276-2285, 2014.
13) Hillaire S, et al : Idiopathic non-cirrhotic intrahepatic portal hypertension in the West : a re-evaluation in 28 patients. Gut 51 : 275-280, 2002.
P.265 掲載の参考文献
1) Willmot FC, Robertson GW : Senecio disease, or cirrhosis of the liver due to senecio poisoning. The Lancet 196 : 848-849, 1920. (DOI : 10.1016/S0140-6736(01)00020-4)
2) DeLeve LD, et al : Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J physiol Gastrointest Liver Physiol 284 : G1045-1052, 2003.
3) 菊田敦, 薬師神公和 : 造血細胞移植後における肝中心静脈閉塞症 (SOS/VOD) の診断と治療. 日本造血細胞移植学会雑誌 5 : 124-137, 2016.
4) Rubbia-Brandt L, et al : Severe Hepatic Sinusoidal Obstruction Associated With Oxaliplatin-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. Ann Oncol 5 : 460-466, 2004.
5) McDonald GB. et al : Venocclusive disease of the liver after bone marrow transplantation : diagnosis, incidence, and predisposing factors. Hepatology 4 : 116-122, 1984.
6) McDonald GB, et al : Veno-occlus ive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993.
8) Mohty M, et al : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 : 906-912, 2016.
10) Bearman SI, et al : Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 89 : 1501-1506, 1997.
11) Shin-Nakai N, et al : Control of hepatic veno-occlusive disease with an antithrombin-III concentrate-based therapy. Pediatr Int 48 : 85-87, 2006.
12) Wiedermann ChJ, Romisch J : The anti-inflammatory actions of antithrombin-a review. Acta Med Austriaca 29 : 89-92, 2002.
13) Al Beihany A, et al : Successful treatment of hepatic veno-occlus ive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 41 : 287-291, 2008.
14) Yakushijin K, et al : Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation : Incidence, risk factors and outcomes, Bone Marrow Transplant 51 : 403-409, 2016.
15) Hubert C, et al : Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases : factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) 15 : 858-864, 2013.
P.268 掲載の参考文献
1) Berzigotti A, et al : Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol 7 : 141-155, 2013.
2) Goodman ZD, Ishak KG : Occlusive venous lesions in alcoholic liver disease. A study of 200 cases. Gastroenterology 83 : 786-796, 1982.
3) Burt AD, MacSween RN : Hepatic vein lesions in alcoholic liver disease : retrospective biopsy and necropsy study. J Clin Pathol 39 : 63-67, 1986.
4) Kishi M, et al : Hepatic veno-occlusive lesions and other histopathological changes of the liver in severe alcoholic hepatitis-a comparative clinicohistopathological study of autopsy cases. Alcohol Clin Exp Res 24 : 74S-80S, 2000.
5) Lawrence TS, et al : Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 : 1237-1248, 1995.
6) Fajardo LF, Colby TV : Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104 : 584-588, 1980.
8) Hautekeete ML, Greets A : The hepatic stellate (Ito) cell : its role in human liver disease. Virchows Arch 430 : 195-207, 1997.
9) Geubel AP, et al : Liver damage caused by therapeutic vitamin A administration : estimate of dose-related toxicity in 41 cases. Gastroenterology 100 : 1701-1709, 1991.
10) James WE, et al : Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest 154 : 349-356, 2018.
11) Shah SR, et al : Case report. Diagnosis of disseminated Mycobacterium avium complex infection by liver biopsy. AIDS Read 10 : 669-672, 2000.
12) Groeschl RT, et al : Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol 109 : 483-486, 2014.
13) Suriawinata AA, Thung SN : Malignant liver tumors. Clin Liver Dis 6 : 527-554, ix, 2002.
14) Wanless IR, Geddie WR : Mineral oil lipogranulomata in liver and spleen. A study of 465 autopsies. Arch Pathol Lab Med 109 : 283-286, 1985.
15) Khanna R, Sarin SK : Non-cirrhotic portal hypertension-diagnosis and management. J Hepatol 60 : 421-441, 2014.
P.273 掲載の参考文献
1) European Association for the Study of the Liver : EASL Clinical Practice Guidelines : Vascular diseases of the liver. J Hepatol 64 : 179-202, 2016.
2) Valla DC : Vascu1ar Disorders of the Liver and Extrahepatic Portal Hypertension. In : Sherlock's Diseases of the Liver and Biliary System, 13th ed (ed by Dooly JS, et al), p214-217, Wiley Blackwell, New Jersey, 2018.
3) 森安史典, ほか : バッド・キアリ症候群診断のガイドライン. 門脈血行異常症ガイドライン 2018年改訂版 (2018年12月13日 Version) (滝川一, 田中篤 : 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」班), p15-18, 2018.
4) 難病情報センター : バッド・キアリ症候群 (指定難病 91). [https://www.nanbyou.or.jp/entry/174]
5) 一般社団法人日本血栓止血学会 : Budd-Chiari症候群 (JAK2V617F含む). [https://www.jsth.org/glossary_detail/?id=20]
6) 石橋啓如, ほか : JAK2遺伝子変異の関与が疑われた非硬変性門脈血栓症に伴う肝外門脈閉塞症の1例. 肝臓 55 : 170-175, 2014.
7) 神田達郎, ほか : Buerger病と門脈圧亢進症を合併した抗リン脂質抗体症候群の1例. 日消誌 92 : 789-793, 1995.
8) Qi X. et al : Prevalence of thrombotic risk factors in Chinese Budd-Chiari syndrome patients : results of a prospective validation study. Eur J Gastroenterol Hepatol 26 : 576-577, 2014.
9) Shrestha SM, et al : Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 11 : 170-179, 1996.
10) Benhamou JP, Valla D : Disorders of the hepatic veins and venules. In : Portal Hypertension (ed by Okuda K, Benhamou JP), p381-392, Springer-Verlag, Tokyo, 1991.
11) Middeldorp S, et al : Does thrombophilia testing help in the clinical management of patients? Br J Haematol 143 : 321-335, 2008.
12) Darwish Murad S, et al : Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 151 : 167-175, 2009.
13) Moucari R, et al : Hepatocellular carcinoma in Budd-Chiari syndrome : characteristics and risk factors. Gut 57 : 828-835, 2008.
14) Sharma S, et al : Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention. J Gastroenterol Hepatol 35 : 654-662, 2020.
P.278 掲載の参考文献
1) Goto K, et al : Familial occurrence of a congenital portosystemic shunt of the portal vein. Hiroshima J Med Sci 66 : 85-90, 2017.
2) 石渡裕俊, ほか : バルーン閉塞下逆行性経静脈的塞栓術で治療しえた非肝硬変性門脈大循環短絡症の2例-肝生検組織像の経過を含めて. 肝臓 43 : 498-506, 2002.
3) 日本門脈圧亢進症学会 (編) : 門脈圧亢進症取扱い規約 改訂第3版, 金原出版, 2013.
4) 真嶋敏光, ほか : 下腸間膜静脈-下大静脈短絡による猪瀬型肝性脳症の1例. 日消外会誌 22 : 843-846, 1989.
5) Matsumoto A, et al : Three-dimensional portography using multislice helical CT is clinically useful for management of gastric fundic varices. AJR Am J Roentgenol 176 : 899-905, 2001.
6) 金川博史, ほか : バルーン下逆行性経静脈的塞栓術 (Ballon-occluded retrograde transvenous obliteration) による胃静脈瘤の1治験例. 日消誌 88 : 1459-1462, 1991.
7) Fukuda T, et al : Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol 12 : 327-336, 2001.
8) Madoff DC, et al : Portal Venous Interventions : State of the Art. Radiology 278 : 333-353, 2016.
9) Mukund A, et al : Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy : initial experience. J Vasc Interv Radiol 23 : 1200-1206, 2012.
10) Laleman W, et al : Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy : a multicenter survey on safety and efficacy. Hepatology 57 : 2448-2457, 2013.
11) 和栗暢生, ほか : 肝性脳症に対するB-RTO. 日門亢会誌 18 : 111-118, 2012.
12) Naeshiro N, et al : Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 29 : 1035-1042, 2014.
13) Jogo A, et al : Factors associated with aggravation of es ophageal varices after B-RTO for gastric varices. Cardiovasc Intervent Radiol 37 : 1243-1250, 2014.
14) 和栗暢生, ほか : B-RTO・PSE同時併用療法の有用性. 日門亢会誌 16 : 231-234, 2010.
15) Honda Y, et al : Portosystemic Encephalopathy without Liver Disease Masquerading as Dementia. Hiroshima J Med Sci 66 : 17-20, 2017.
P.282 掲載の参考文献
1) Barzilai R, Kleckner MS Jr : Hemocholecyst following ruptured aneurysm of portal vein ; report of a case. AMA Arch Surg 72 : 725-727, 1956.
2) Doust BD, Pearce JD : Gray-scale ultrasonic properties of the normal and inflamed pancreas. Radiology 120 : 653-657, 1976.
3) Koc Z, et al : Portal vein variations : clinical implications and frequencies in routine abdominal multidetector CT. Diagn Interv Radiol 13 : 75-80, 2007.
4) Lopez-Machado E, et al : Aneurysms of the portal venous system : ultrasonography and CT findings. Eur J Radiol 26 : 210-214, 1998.
5) Ma R, et al : Extra-hepatic portal vein aneurysm : A case report, overview of the literature and suggested management algorithm. Int J Surg Case Rep 3 : 555-558, 2012.
6) Cho SW, et al : Extrahepatic portal vein aneurysm--report of six patients and review of the literature. J Gastrointest Surg 12 : 145-152, 2008.
7) Gallego C, et al : Congenital and acquired anomalies of the portal venous system. Radiographics 22 : 141-159, 2002.
8) Fulcher A, Turner M : Aneurysms of the portal vein and superior mesenteric vein, Abdom Imaging 22 : 287-292, 1997.
9) Gallagher DM, et al : In utero diagnosis of a portal vein aneurysm. J Clin Ultrasound 21 : 147-151, 1993.
10) Ahmed O, et al : Feasibility and safety of non-operative management of portal vein aneurysms : a thirty-five year experience. HPB (Oxford), 2020. (DOI : 10.1016/j.hpb2020.05.006)
11) Iimuro Y, et al : Hemodynamic analysis and treatment of an enlarging extrahepatic portal aneurysm : report of a case. Surg Today 45 : 383-389, 2015.
12) Tana C, et al : Contrast-enhanced ultrasound in portal venous system aneurysms : a multi-center study. World J Gastroenterol 20 : 18375-18383, 2014.
13) Watanabe Y, et al : Portal vein aneurysm with complete spontaneous regression after 10 years using conservative treatment. Clin J Gastroenterol 13 : 940-945, 2020.
P.286 掲載の参考文献
1) Doust BD, Pearce JD : Gray-scale ultrasonic properties of the normal and inflamed pancreas. Radiology 120 : 653-657, 1976.
2) Ohnishi K, et al : Aneurysm of the intrahepatic branch of the portal vein. Report of two cases. Gastroenterology 86 : 169-173, 1984.
3) Barzilai R, Kieckner MS : Hemocholecyst following ruptured aneurysni of portal vein ; report of a case. AMA Arch Surg 72 : 725-727, 1956.
5) Laurenzi A, et al : Portal vein aneurysm : What to know. Dig Liver Dis 47 : 918-923, 2015.
6) Gallego C, et al : Congenital and acquired anomalies of the portal venous system. Radiographics 22 : 141-159, 2002.
7) Yang DM, et al : Portal vein aneurysm of the umbilical p ortion : imaging features and the reiationship with portal vein anomalies. Abdom Imaging 28 : 62-67, 2003.
8) Schwope RB, et al : Portal vein aneurysms : a case series with literature review. J Radiol Case Rep 4 : 28-38, 2010.
9) Takayasu K, et al : Spontaneous portal. hepatic venous shunt via an intrahepatic portal vein aneurysm. Gastroenterology 86 : 945-948, 1984.
10) Rafailidis V, Sidhu PS : Vascular ultrasound, the potential of integration of multiparametric ultrasound into routine clinical practice. Ultrasound 26 : 136-144, 2018.
11) Koc Z, et al : Portal venous system aneurysms : imaging, clinical findings, and a possible new etiologic factor. AJR Am J Roentgenol 189 : 1023-1030, 2007.
12) Lupescu I, et al : CT and MRI of acquired portal venous system anomalies. J Gastrointestin Liver Dis 15 : 393-398, 2006.
13) Shrivastava A, et al : Giant Intrahepatic Portal Vein Aneurysm : Leave it or Treat it? J Clin Exp Hepatol 7 : 71-76, 2017.
14) Shukla PA, et al : Percutaneous Embolization of an Intrahepatic Portal Vein Aneurysm. J Vasc Interv Radiol 27 : 1747-1749, 2016.
15) Moreno JA, et al : Extrahepatic portal vein aneurysm. J Vasc Surg 54 : 225-226, 2011.
P.292 掲載の参考文献
1) Howard ER, Davenport M : Congenital extrahepatic portocaval shunts-the Abernethy malformation. J Pediatr Surg 32 : 494-497, 1997.
2) Sanada Y, Mizuta K : Congenital absence of the portal vein : translated version. J Hepatobiliary Pancreat Sci 25 : 359-369, 2018.
3) Morgan G, Superina R : Congenital absence of the portal vein : two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg 29 : 1239-1241, 1994.
4) Alonso-Gamarra E, et al : Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts : a comprehensive review. Radiographics 31 : 707-722, 2011.
5) Sokollik C, et al : Congenital portosystemic shunt : characterization of a multisystem disease. J Pediatr Gastroenterol Nutr 56 : 675-681, 2013.
7) Esscher T : Preduodenal portal vein--a cause of intestinal obstruction? J Pediatr Surg 15 : 609-612, 1980.
8) Braun P, et al : Preduodenal portal vein : a significant entity? Report of two cases and review of the literature. Can J Surg 17 : 316-319, 322, 1974.
9) Mordehai J, et al : Preduodenal portal vein causing duodenal obstruction associated with situs inversus, intestinal malrotation, and polysplenia : A case report. J Pediatr Surg 37 : E5. 2002.
10) Latha GA, et al : Preduodenal Portal Vein in Adult with Polysplenia Syndrome Revisited with a Case Report. Indian J Surg 76 : 137-142, 2014.
12) Hashimoto T, Yura J : Biliary atresia with preduodenal portal vein : a new hypothesis in the development of preduodenal portal vein. Jpn J Pediatr Surg 11 : 1301-1310, 1979.
13) Brook W, Gardner M : Anteroposition of the portal vein and spontaneous passage of gall-stones. Case report and embryological hypothesis. Br J Surg 59 : 737-739, 1972.
14) Goussous N, Cunningham SC : Prepancreatic postduodenal portal vein : a case report and review of the literature. J Med Case Rep 11 : Article number 2, 2017.
15) Matsumoto Y, et al : Anomalies of the portal venous system ; pathogenesis and its surgical implications. Jpn J Gastroenterol Surg 16 : 2112-2121, 1983.
16) Snavely JG, Breakell ES : Fatal hemorrhage from esophageal varices, due to malformations and congenital stenoses in portal venous system. Am J Med 16 : 459-464, 1954.
17) Miyaki T, et al : Aberrant course of the left gastric vein in the human. Possibility of a persistent left portal vein. Acta Anat (Basel) 130 : 275-279, 1987.
P.297 掲載の参考文献
1) Vilstrup H, et al : Hepatic encephalopathy in chronic liver disease : 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60 : 715-735, 2014.
2) Sharma P, et al : Critical flicker frequency : diagnostic tool for minimal hepatic encephalopathy. J Hepatol 47 : 67-73, 2007.
3) Shaw J, Bajaj JS : Covert Hepatic Encephalopathy : Can My Patient Drive? J Clin Gastroenterol 51 : 118-126, 2017.
4) Hanai T, et al : Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis. J Clin Med 9 : 1013, 2020. [DOI : 10. 3390/jcm9041013]
5) Gluud LL, et al : Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 5 : CD001939, 2017.
6) Gluud LL, et al : Nonabsorbable disaccharides for hepatic encephalopathy : A systematic review and meta-analysis. Hepatology 64 : 908-922, 2016.
7) Kimer N, et al : Systematic review with meta-analysis : the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 40 : 123-132, 2014.
8) Suzuki K, et al : Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy : A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res 48 : 411-423, 2018.
9) Hanai T, et al : Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. Nutrients 12 : 1915, 2020. [DOI : 10. 3390/nu12071915]
11) Takuma Y, et al : Clinical trial : oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther 32 : 1080-1090, 2010.
12) Christensen E, et al : Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. Scand J Gastroenterol 24 : 999-1006, 1989.
14) Hanai T, et al : Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan : A propensity score-matching analysis. J Gastroenterol Hepatol 34 : 1809-1816, 2019.
P.301 掲載の参考文献
1) Vauthey JN et al : The arterioportal fistula syndrome : clinicopathologic features, diagnosis, and therapy. Gastroenterology 113 : 1390-1401, 1997.
2) Weigert VC : In die milzvene geborstenes aneurysma einer milzarterie. Archiv f Pathol Anat 104 : 26-30, 1886.
3) 清末一路, ほか : 肝内血管短絡 (Rendu-Osler-Weber病を含めて). 消化器画像 4 : 659-669, 2002.
4) 比嘉花絵, ほか : 肝動脈門脈シャント形成に至った胸部鋭的外傷による肝損傷の1例. 日臨外会誌 81 : 1156-1160, 2020.
6) 高野正幹, ほか : 造影超音波が有用であった動脈門脈短絡を伴う肝血管腫の一症例. 超音波検査技術 35 : 294-297, 2010.
7) Okuda K, et al : Frequency of intrahepatic arteriovenous fistula as a sequela to percutaneous needle puncture of the liver. Gastroenterol 74 : 1204-1207, 1978.
8) 大座紀子, ほか : 肝生検後35年経過して発症し経カテーテル的肝動脈塞栓術によって門脈圧亢進が著明に改善した肝内動門脈瘻の1例. 肝臓 49 : 506-511, 2008.
9) Guzman EA, et al : Arterioportal fistulas : introduction of a novel classification with therapeutic implications. J Gastrointest Surg 10 : 543-550, 2006.
10) 上田和彦, ほか : A-Pシャントの画像診断. 消化器画像 9 : 133-142, 2007.
11) Sun HY, et al : Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≦ 2 cm in diameter) from arterial enhancing psedolesions : special emphasis on hepatobiliary phase imaging. Invest Radiol 45 : 96-103, 2010.
12) Takata H, et al : Successful surgical treatment for intrahepatic arterioportal fistula with severe portal hypertension : a case report. Surg Case Rep 5 : 67, 2019.
13) 福田健, ほか : TIPSを行った肝内びまん性動脈門脈短絡を合併したアルコール性肝硬変の2症例. 肝臓 52 : 662-670, 2011.
14) Mamada Y, et al : Major arterioportal shunt caused by hepatocellular carcinoma. J Nippon Med Sch 74 : 314-318, 2007.
15) 吉田寛 : 門脈圧亢進症に対する手術療法とIVR. 日消誌 116 : 404-411, 2019.
P.305 掲載の参考文献
1) Lane MJ, et al : Spontaneous intrahepatic vascular shunts. AJR Am J Roentgenol 174 : 125-131, 2000.
3) Memeo M, et al : Hereditary haemorrhagic telangiectasia : study of hepatic vascular alterations with multi-detector row helical CT and reconstruction programs. Radiol Med 109 : 125-138, 2005.
4) Buscarini E, et al : Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia-results of extensive screening. Ultraschall Med 25 : 348-355, 2004.
5) Ocran K, et al : Sonographic findings in hepatic involvement of hereditary haemorrhagic telangiectasia, Ultraschall Med 25 : 191-194, 2004.
6) Ianora AA, et al : Hereditary hemorrhagic telangiectasia : multi-detector row helical CT assessment of hepatic involvement. Radiology 230 : 250-259, 2004.
7) Bourgeois N, et al : Osler-Weber-Rendu disease associated with hepatic involvement and high output heart failure. J Clin Gastroenterol 12 : 236-238, 1990.
9) Bauer T, et al : Liver transplantation for hepatic arteriovenous malformation in hereditary haemorrhagic telangiectasia. J Hepatol 22 : 586-590, 1995.
11) Buscarini E, et al : High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 30 : 1089-1097, 2004.
13) Vazquez C, et al : Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS ONE 15 : e0228486, 2020.
14) Dupuis-Girod S, et al : Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307 : 948-955, 2012.
15) Caselitz M, et al : Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease). Gut 42 : 123-126, 1998.
16) Chavan A, et al : Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol 14 : 2079-2085, 2004.
17) Chavan A, et al : Complications and clinical outcome of hepatic artery embolisation in patients with hereditary haemorrhagic telangiectasia. Eur Radiol 23 : 951-957, 2013.
18) Hisamatsu K, et al : Peripheral arterial coil embolization for hepatic arteriovenous malformation in Osler-Weber-Rendu disease ; useful for controlling high output heart failure, but harmful to the liver. Intern Med 38 : 962-968, 1999.
19) 明石建, ほか : A-P・A-Vシャントをともなう肝海綿状血管腫に対し肝動脈・門脈塞栓後肝切除を施行した1例. 日本外科系連合学会誌 21 : 903-906, 1996.
20) Lerut J, et al : Liver transplantation for hereditary hemorrhagic telangiectasia : Report of the European liver transplant registry. Ann Surg 244 : 854-862 ; discussion 862-864, 2006.
P.309 掲載の参考文献
1) Waseem N, Chen PH : Hypoxic Hepatitis : A Review and Clinical Update. J Clin Transl Hepatol 4 : 263-268, 2016.
2) Tanaka Y, et al : Cardioembolic stroke followed by isolated celiac artery thromboembolism. Intern Med 46 : 1463-1466, 2007.
3) Ueda T, et al : Hepatic infarction caused by an embolus from an atherosclerotic lesion--a case report. Angiology 49 : 165-168, 1998.
4) Abboud H, et al : Prevalence and determinants of subdiaphragmatic visceral infarction in patients with fatal stroke. Stroke 38 : 1442-1446, 2007.
5) Slaoui T, et al : Prevalence of subdiaphragmatic visceral infarction in cardioembolic stroke. Neurology 74 : 1030-1032, 2010.
6) Sakhel K, et al : Liver infarction in a woman with systernic lupus erythematosus and secondary anti-phospholipid and HELLP syndrome. Scand J Rheumatol 35 : 405-408, 2006.
7) Birrer R, et al : Hypoxic hepatopathy : pathophysiology and prognosis. Intern Med 46 : 1063-1070, 2007.
8) Zocco MA, et al : Thrombotic risk factors in patients with liver cirrh osis : correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51 : 682-689, 2009.
P.313 掲載の参考文献
1) Hossain A, et al : Visceral artery aneurysms : experience in a tertiary-care center. Am Surg 67 : 432-437, 2001.
2) Pasha SF, et al : Splanchnic artery aneurysms. Mayo Clin Proc 82 : 472-479, 2007.
3) O'Driscoll D, et al : Hepatic artery aneurysm. Br J Radiol 72 : 1018-1025, 1999.
6) 宇野耕治, ほか : 動脈塞栓術にて治癒しえた肝動脈瘤胆道穿破の1例. 日本消化器病学会雑誌 91 : 115-118, 1994.
7) Abbas MA, et al : Hepatic artery aneurysm : factors that predict complications. J Vasc Surg 38 : 41-45, 2003.
8) 谷合信彦, ほか : 消化器外科領域における消化管・腹腔内動脈出血に対するIVR. 日本腹部救急医学会誌 25 : 815-820, 2005.
9) Sandblom P, Mirkovitch V : Hemobilia : some salient features and their causes. Surg Clin North Am 57 : 397-408, 1977.
10) 阿部展次, ほか : 胆道系-病態生理-動脈瘤. 胆と膵 25 (増刊) : 766-769, 2004.
11) 高橋直子, ほか : 腹部内臓動脈瘤の治療検討. 日本血管外科学会雑誌 19 : 487-493, 2010.
12) Curran FT, Taylor SA : Hepatic artery aneurysm. Postgrad Med J 62 : 957-959, 1986.
13) 山田翔, ほか : 血管内治療と外科治療で救命できた固有肝動脈瘤破裂の1例. 日本消化器外科学会雑誌 51 : 445-452, 2018.
14) 森景則保 : 内臓動脈瘤に対する当科の治療戦略-手術治療 (外科的手術, 血管内治療) と保存的治療の予後-. 日本血管外科学会雑誌 22 : 633-639, 2013.
15) 浅井浩司, ほか : 無症候性肝動脈瘤に対してステント支援下コイル塞栓術を施行した1例. 臨牀と研究 95 : 557-560, 2018.

VII 肝内胆汁うっ滞症

P.322 掲載の参考文献
1) Kagawa T : Hepatobiliary transport of bile acids. In : Bile Acids in Gastroenterology, Basic and Clinical (ed by Tazuma S, Takikawa H), p9-25, Springer, 2017.
2) Kagawa T, et al : Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol 294 : G58-67, 2008.
3) Dixon PH, et al : An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep 7 : 11823, 2017.
4) Stattermayer AF, et al : Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol 73 : 651-663, 2020.
5) Lang C, et al : Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17 : 47-60, 2007.
6) Kagawa T, et al : No contribution of the ABCB11 p.444A polymorphism in Japanese patients with drug-induced cholestasis. Drug Metab Dispos 43 : 691-697, 2015.
7) Vaz FM, et al : Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency : conjugated hypercholanemia without a clear clinical phenotype. Hepatology 61 : 260-267, 2015.
8) van de Steeg E, et al : Complete OATP1Bl and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122 : 519-528, 2012.
9) Kagawa T, et al : Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype. Hum Mutat 36 : 327-332, 2015.
10) Kagawa T, et al : Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms. Hepatology 65 : 1065-1068, 2017.
11) Sultan M, et al : Organic solute transporter-β (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis. Hepatology 68 : 590-598, 2018.
P.327 掲載の参考文献
1) Kamath BM, et al : Consequences of JAG1 mutations. J Med Genet 40 : 891-895, 2003.
2) 須磨崎亮 : Alagille症候群など遺伝性胆汁うっ滞性疾患の診断ガイドライン作成, 実態調査並びに. 生体資料のバンク化に関する研究, 平成21年度総括・分担研究報告書 : 厚生労働科学研究費補助金難治性疾患克服研究事業, 2010.
3) Tsai EA, et al : THBS2 Is a Candidate Modifier of Liver Disease Severity in Alagille Syndrome. Cell Mol Gastroenterol Hepatol 2 : 663-675.e2, 2016.
4) Subramaniam P, et al : Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. J Pediatr Gastroenterol Nutr 52 : 84-89, 2011.
5) Emerick KM, et al : Features of Alagille syndrome in 92 patients : frequency and relation to prognosis. Hepatology (Baltimore, Md) 29 : 822-829, 1999.
6) McElhinney DB, et al : Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAGI mutation and/or Alagille syndrome. Circulation 106 : 2567-2574, 2002.
7) Kamath BM, et al : Vascular anomalies in Alagille syndrome : a significant cause of morbidity and mortality. Circulation 109 : 1354-1358, 2004.
8) Okuno T, et al : Temporal bone histopathologic findings in Alagille's syndrome. Arch Otolaryngol Head Neck Surg 116 : 217-220, 1990.
9) Nischal KK, et al : Ocular ultrasound in Alagille syndrome : a new sign. Ophthalmology 104 : 79-85, 1997.
10) Olsen IE, et al : Deficits in size-adjusted bone mass in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 40 : 76-82, 2005.
11) Kung AW, et al : Association of JAG1 with bone mineral density and osteoporotic fractures : a genome-wide association study and follow-up replication studies. Am J Hum Genet 86 : 229-239, 2010.
12) Kamath BM, et al : A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr 50 : 526-530, 2010.
13) Kamath BM, et al : Renal anomalies in Alagille syndrome : a disease-defining feature. Am J Med Genet A 158A : 85-89, 2012.
14) Mitchell E, et al : Alagille Syndrome. Clin Liver Dis 22 : 625-641, 2018.
15) Lykavieris P, et al : Outcome of liver disease in children with Alagille syndrome : a study of 163 patients. Gut 49 : 431-435, 2001.
P.331 掲載の参考文献
1) Bull LN, Thompson RJ : Progressive Familial Intrahepatic Cholestasis. Clin liver dis 22 : 657-669, 2018.
2) Jacquemin E : Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 36 (Suppl 1) : S26-35, 2012.
3) Paulusma CC, et al : Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44 : 195-204, 2006.
5) Togawa T, et al : Molecular Genetic Dissection and Neonatal/Infantile Intrahepatic Cholestasis Using Targeted Next-Generation Sequencing. J Pediatr 171 : 171-177.e1-4, 2016.
6) Hayashi H, et al : Assessment of ATP8B1 Deficiency in Pediatric Patients With Cholestasis Using Peripheral Blood Monocyte-Derived Macrophages. EBioMedicine 27 : 187-199, 2018.
7) Summerskill WH, Walshe JM : Benign recurrent intrahepatic "obstructive" jaundice. Lancet (London, England) 2 : 686-690, 1959.
8) Lucena JF, et al : A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124 : 1037-1042, 2003.
9) Wang KS, et al : Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 65 : 1645-1654, 2017.
10) Hori T, et al : Living-donor liver transplantation for progressive familial intrahepatic cholestasis. World J Surg 35 : 393-402, 2011.
11) Usui M, et al : Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1 : a case report. Pediatr Transplant 13 : 611-614, 2009.
12) Siebold L, et al : Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease). Liver Transpl 16 : 856-863, 2010.
14) Naoi S, et al : Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr 164 : 1219-1227.e3. 2014.
15) Strautnieks SS, et al : Severe bile salt export pump deficiency : 82 different ABCB11 mutations in 109 families. Gastroenterology 134 : 1203-1214, 2008.
P.335 掲載の参考文献
1) Aagenaes O, et al : Hereditary recurrent intrahepatic cholestasis from birth. Arch Dis Child 43 : 465-471, 1968.
3) Aagenaes O : Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to adult age. Scand J Gastroenterol 33 : 335-345, 1998.
4) Drivdal M, et al : Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome). Scand J Gastroenterol 41 : 469-475, 2006.
5) Drivdal M, et al : Do patients with lymphoedema cholestasis syndrome 1/Aagenaes syndrome need dietary counselling outside cholestatic episodes? Clin Nutr 29 : 525-530, 2010.
6) Drivdal M, et al : A nine year follow-up study of patients with lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome). Scand J Clin Lab Invest 78 : 566-574, 2018.
7) Shah S, et al : CCBE1 mutation in two siblings, one manifesting lymphedema-cholestasis syndrome, and the other, fetal hydrops. PLoS One 8 : e75770, 2013.
8) Bagesund M, et al : Dental care and oral health in Aagenaes syndrome/lymphedema cholestasis syndrome 1. Spec Care Dentist 35 : 83-89, 2015.
P.340 掲載の参考文献
3) Chagnon P, et al : A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis. Am J Hum Genet 71 : 1443-1449, 2002.
4) Freed EF, et al : NOL11, implicated in the pathogenesis of North American Indian childhood cirrhosis, is required for pre-rRNA transcription and processing. PLoS Genet 8 : e1002892, 2012.
5) Wilkins BJ, et al : p53-mediated biliary defects caused by knockdown of cirh1a, the zebrafish homolog of the gene responsible for North American Indian Childhood Cirrhosis. PLoS One 8 : e77670, 2013.
6) Chen HL, et al : Jaundice revisited : recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J Biomed Sci 25 : 75, 2018.
7) Girard M, et al : DCDC2 Mutations Cause Neonatal Sclerosing Cholangitis. Hum Mutat 37 : 1025-1029, 2016.
8) Grammatikopoulos T, et al : Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis. J Hepatol 65 : 1179-1187, 2016.
P.345 掲載の参考文献
2) Ornvold K, et al : Fatal familial cholestatic syndrome in Greenland Eskimo children. A histomorphological analysis of l6 cases. Virchows Arch A Pathol Anat Histopathol 415 : 275-281, 1989.
3) Clayton RJ, et al : Byler's disease : fatal familial intrahepatic cholestasis in an Amish kindred. (Abstract) J Pediat 67 : 1025-1028. 1965.
4) Clayton RJ, et al : Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis child 117 : 112-124, 1969.
6) Klomp LW, et al : A missense mutation in FIC1 is associated with greenland familial cholestasis. Hepatology 32 : 1337-1341, 2000.
7) Klomp LW, et al : Characterizati on of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 40 : 27-38, 2004.
8) Nielsen IM, Eiberg H : Cholestasis Familiaris Groenlandica : an epidemiological, clinical and genetic study. Int J Circumpolar Health 63 (Suppl 2) : 192-194, 2004.
9) Henkel SA, et al : Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol 11 : 450-463, 2019.
10) Bull LN. Thompson RJ : Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis 22 : 657-669, 2018.
11) Baker A, et al : Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 43 : 20-36, 2019.
12) Chen HL, et al : Jaundice revisited : recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J Biomed Sci 25 : 75, 2018.
13) Hayashi H, et al : Assessment of ATP8B1 Deficiency in Pediatric Patients With Cholestasis Using Peripheral Blood Monocyte-Derived Macrophages. EBioMedicine 27 : 187-199, 2018.
14) Hasegawa Y, et al : Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1. Orphanet J Rare Dis 9 : 89, 2014.
P.350 掲載の参考文献
1) 小児慢性特定疾病情報センター : 先天性胆汁酸代謝異常症 (告示番号 105). [https://www.shouman.jp/disease/details/08_02_038/]
2) Heubi JE, et al : Inborn Errors of Bile Acid Metabolism. Clin Liver Dis 22 : 671-687, 2018.
3) 本多彰, 田中直見 : 胆汁酸の生成・分泌機構とその異常. The Lipid 17 : 113-119, 2006.
4) Setchell KD, Heubi JE : Defects in bile acid biosynthesis-diagnosis and treatment. J Pediatr Gastroenterol Nutr 43 Suppl 1 : S17-22, 2006.
6) 入戸野博, ほか : 3β-ヒドロキシ-Δ5-C27-ステロイド・デヒドロゲナーゼ/イソメラーゼ欠損症 : ビリルビン・胆汁酸代謝異常. 先天性胆汁酸生合成異常症. コレステロール以外のステロールの蓄積. 別冊日本臨牀新領域別症候群シリーズ No.20v 先天代謝異常症候群 (第2版) 下, p372-375, 日本臨牀社, 2012.
7) Subramaniam P, et al : Variable clinical spectrum of the most common inborn error of bile acid metabolism-3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenterol Nutr 50 : 61-66, 2010.
8) 木村昭彦 : オキシステロール7α-ヒドロキシラーゼ欠損症 : ビリルビン・胆汁酸代謝異常. 先天性胆汁酸生合成異常症, コレステロール以外のステロールの蓄積. 別冊日本臨牀新領域別症候群シリーズ No. 20v 先天代謝異常症候群 (第2版) 下, p381-385, 日本臨牀社, 2012.
9) Chen JY, et al : AKR1D1 and CYP7B1 mutations in patients with inborn errors of bile acid metabolism : Possibly underdiagnosed diseases. Pediatr Neonatol 61 : 75-83, 2020.
10) Mizuochi T, et al : Successful heterozygous living donor liver transplantation for an oxysterol 7α-hydroxylase deficiency in a Japanese patient. Liver Transpl 17 : 1059-1065, 2011.
12) Heubi JE, et al : Treatment of bile acid amidation defects with glycocholic acid. Hepatology 61 : 268-274, 2015.
P.357 掲載の参考文献
1) Saheki T, et al : Hereditary disorders of the urea cycle in man : biochemical and molecular approaches. Rev Physiol Biochem Pharmacol 108 : 21-68. 1987.
3) Yasuda T, et al : Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum Genet 107 : 537-545, 2000.
4) Yamaguchi N, et al : Screening of SLC25A13 mutations in early and late onset patients with citrin deficiency and in the Japanese population : Identification of two novel mutations and establishment of multiple DNA diagnosis methods for nine mutations. Hum Mutat 19 : 122-130, 2002.
5) Okano Y, et al : Current treatment for citrin deficiency during NICCD and adaptation/compensation stages : Strategy to prevent CTLN2. Mol Genet Metab 127 : 175-183, 2019.
6) Song YZ, et al : Failure to thrive and dyslipidemia caused by citrin deficiency. a novel clinical phenotype. Chin J Contemp Pediatr 11 : 328-332, 2009.
7) Song YZ, et al : Neonatal intrahepatic cholestasis caused by citrin deficiency : efficacy of therapeutic formulas and update of clinical outcomes. Jpn J Inherit Metab Dis 26 : 57-69, 2010.
8) 岡野善行 : シトリン欠損症. 小児内科 48 : 907-910, 2016.
9) Tamamori A, et al : Neonatal intrahepatic cholestasis caused by citrin deficiency : severe hepatic dysfunction in an infant requiring liver transplantation. Eur J Pediatr 161 : 609-613, 2002.
12) Tanaka T, et al : Sodium pyruvate treatment for persistent NICCD. Jpn J Inher Metab Dis 33 : 219, 2017.
13) Mutoh K et al : Treatment of a citrin-deficient patient at the early stage of adult-onset type II citrullinaemia with arginine and sodium pyruvate. J Inherit Metab Dis 31 Suppl 2 : S343-347, 2008.
14) 日本肝移植研究会 : 肝移植症例登録報告. 移植 53 : 109-123, 2018.
P.361 掲載の参考文献
1) Gilbert A : La cholemie simple familiale. Semaine Med 21 : 241-243, 1901.
3) Owens D, Evans J : Population studies on Gilbert's syndr ome. J Med Genet 12 : 152-156, 1975.
4) Sieg A, et al : [Prevalence of Gilbert's syndrome in Germany]. Dtsch Med Wochenschr 112 : 1206-1208, 1987.
7) Maruo Y, et al : Association of ne onatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 103 : 1224-1227, 1999.
8) Maruo Y, et al : Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol 31 : 403-408, 2016.
9) Wasserman E. et al : Severe CPT-11 toxicity in patients with Gilbert's syndrome : two case reports. Ann Oncol 8 : 1049-1051, 1997.
11) Maruo Y, et al : Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr 165 : 36-41. eL 2014.
12) Kamal S, et al : The frequency, clinical course, and health related quality of life in adults with Gilbert's syndrome : a longitudinal study. BMC Gastroenterol 19 : 22, 2019.
13) Madonia S, et al : Letter : should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Aliment Pharmacol Ther 43 : 1021-1022, 2016.
14) Deterding K, et al : Gilbert's syndrome and antiviral therapy of hepatitis C. Ann Hepatol 8 : 246-250, 2009.
P.364 掲載の参考文献
3) Seppen J, et al : Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 94 : 2385-2391, 1994.
4) Aono S, et al : Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 197 : 1239-1244, 1993.
5) Bartlett MG, Gourley GR : Assessment of UGT polymorphisms and neonatal jaundice. Semin Perinatol 35 : 127-133, 2011.
6) Childs B, et al : Glucuronic acid conjugation by patients with familial nonhemolytic jaundice and their relatives. Pediatrics 23 : 903-913, 1959.
7) Crigler JF, Najjar VA : Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 10 : 169-180, 1952.
8) Arias IM, et al : Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 47 : 395-409, 1969.
9) Moscowitz A, et al : The in vitro conversion of bile pigments to the urobilinoids by a rat clostridia species as compared with the human fecai flora. 3. Natural d-urobilin, synthetic i-urobilin, and synthetic i-urobilinogen. Biochem Med 4 : 149-164, 1970.
10) Mitchell E, et al : Hepatic Parenchymal Injury in Crigler-Najjar Type I. J Pediatr Gastroenterol Nutr 66 : 588-594, 2018.
11) Sugatani J, et al : The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33 : 1232-1238, 2001.
14) Van der Veere CN, et al : Oral calcium phosphate : a new therapy for Crigler-Najjar disease? Gastroenterology 112 : 455-462, 1997.
15) Toietta G, et al : Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 102 : 3930-3935, 2005.
P.367 掲載の参考文献
1) Rotor AB, et al : Familial nonhemolytic jaundice with direct van den Bergh reaction. Acta Med Phil 5 : 37-49, 1948.
3) Cui Y, et al : Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276 : 9626-9630, 2001.
5) Strassburg CP : Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 24 : 555-571, 2010.
6) Maeda K : Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull 38 : 155-168, 2015.
P.369 掲載の参考文献
2) Strassburg CP : Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 24 : 555-571, 2010.
3) Dubin IN : Chronic idiopathic jaundice ; areview of fifty cases. Am J Med 24 : 268-292, 1958.
5) Shani M, et al : Dubin-Johnson syndrome in Israel. 1. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 39 : 549-567, 1970.
6) Paulusma CC, et al : A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25 : 1539-1542, 1997.
7) Memon N, et al : Inherited disorders of bilirubin clearance. Pediatr Res 79 : 378-386, 2016.
8) Jemnitz K, et al : ABCC2/Abcc2 : a multispecific transporter with dominant excretory functions. Drug Metab Rev 42 : 402-436, 2010.
9) Haimi-Cohen Y, et al : Dubin-Johnson syndrome as a cause of neonatal jaundice : the importance of coproporphyrins investigation. Clin Pediatr 37 : 511-513, 1998.
P.371 掲載の参考文献
1) Arias IM, et al : Transient familial neonatal hyperbilirubinemia. J Clin Invest 44 : 1442-1450, 1965.
2) Maruo Y, et al : Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr 165 : 36-41.e1, 2014.
3) Lathe GH, Ruthven CRJ : Factors affecting the rate of coupling of bilirubin and conjugated bilirubin in the van de Bergh reaction. J Clin Pathol 11 : 155-161, 1958.
P.376 掲載の参考文献
1) Wilmore DW, Dudrick SJ : Growth and development of an infant receiving all nutrients exclusively by vein. JAMA 203 : 860-864, 1968.
2) Xu ZW, Li YS : Pathogenesis and treatment of parenteral nutrition-associated liver disease. Hepatobiliary Pancreat Dis Int 11 : 586-593, 2012.
3) Lauriti G, et al : Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children : a systematic review. JPEN J parenter Enteral Nutr 38 : 70-85, 2014.
4) Healy CM, et al : Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 121 : 703-710, 2008.
5) Tu H, et al : FXR, a bile acid receptor and biological sensor. Trends Cardiovasc Med 10 : 30-35, 2000.
7) Ramirez-Perez O, et al : The role of the gut microbiota in bile acid metabolism. Ann Hepatol 16 (Suppl 1 : s3-105) : s15-s20, 2017.
8) de Belle RC, et al : Intestinal absorption of bile salts : immature development in the neonate. J Pediatr 94 : 472-476, 1979.
9) Suchy FJ, et al : Taurocholate transport and Na+ -K+ -ATPase activity in fetal and neonatal rat liver plasma membrane vesicles. Am J Physiol 251 (5 Pt 1) : G665-G673, 1986.
10) Niinikoski H, et al : Onset of small intestinal atrophy is associated with reduced intestinal blood flow in TPN-fed neonatal piglets. J Nutr 134 : 1467-1474, 2004.
11) Raman M, et al : Parenteral nutrition and lipids. Nutrients 9 : 388, 2017.
13) 胆道閉鎖症診療ガイドライン (日本胆道閉鎖症研究会編), へるす出版, 2018.
14) Martindale RG, et al : Summary of proceedings and expert consensus statements from the international summit'Lipids in Parenteral Nutrition'. JPEN J Parenter Enteral Nutr 44 (Suppl 1) : S7-S20, 2020.
15) Willis TC, et al : High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J parenter Enteral Nutr 34 : 32-37, 2010.
P.381 掲載の参考文献
1) Wachs ME, et al : Adult living donor liver transplantation using a right hepatic lobe. Transplantation 66 : 1313-1316, 1998.
2) Dulundu E, et al : Duct-to-duct biliary reconstruction in adult living-donor liver transplantation. Transplantation 78 : 574-579, 2004.
3) Ishiko T, et al : Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. Ann Surg 236 : 235-240, 2002.
4) Akamatsu N, et al : Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation : a systematic review of the incidence, risk factors and outcome. Transpl Int 24 : 379-392, 2011.
5) Kyoden Y, et al : Incidence and management of biliary complications after adult-to-adult living donor liver transplantation. Clin Transplant 24 : 535-542, 2010.
6) Kasahara M, et al : Biliary reconstruction in right lobe living-donor liver transplantation : Comparison of different techniques in 321 recipients. Ann Surg 243 : 559-566, 2006.
7) Chok KS, et al : Bile duct anastomotic stricture after adult-to-adult right lobe living donor liver transplantation. Liver Transpl 17 : 47-52, 2011.
8) Hyodo T, et al : CT and MR cholangiography : advantages and pitfalls in perioperative evaluation of biliary tree. Br J Radiol 85 : 887-896, 2012.
9) Arain MA, et al : Advances in endoscopic management of biliary tract complications after liver transplantation. Liver Transpl 19 : 482-498, 2013.
10) Tashiro H, et al : Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation : causes and treatment. World J Surg 31 : 2222-2229, 2007.

最近チェックした商品履歴

Loading...